Optimizing Basic pH Reversed-Phase Chromatography for Deep diGly Peptide Fractionation in Ubiquitinome Analysis

Abstract

This article provides a comprehensive guide for researchers and drug development professionals on the application of basic pH reversed-phase chromatography (bRPLC) for the fractionation of diglycine (diGly)-modified peptides, a critical step in large-scale ubiquitinome analysis. It covers the foundational principles of ubiquitin signaling and the role of diGly remnant enrichment, details optimized bRPLC methodologies that enable the identification of over 90,000 diGly sites, presents practical troubleshooting for common chromatographic and MS-detection issues, and validates the performance of bRPLC against alternative strategies. By integrating these aspects, the content serves as a definitive resource for implementing robust, high-sensitivity workflows to uncover novel ubiquitination biology in biomedical research.

The Critical Role of Basic pH RPLC in Modern Ubiquitinome Research

Protein ubiquitination is a crucial post-translational modification (PTM) that regulates diverse cellular functions, including protein stability, activity, and localization [1]. This modification involves the covalent attachment of a small, 76-amino acid protein called ubiquitin (Ub) to substrate proteins. The process is enzymatic, involving a cascade of E1 (activating), E2 (conjugating), and E3 (ligating) enzymes [1]. The reverse reaction is catalyzed by deubiquitinases (DUBs) [1]. Given its involvement in numerous pathologies, such as cancer and neurodegenerative diseases, comprehensive analysis of protein ubiquitination has become a major focus in proteomic research [1].

A significant breakthrough in ubiquitination analysis came from understanding the diGly (diglycine) signature. When ubiquitinated proteins are digested with the protease trypsin, a characteristic remnant—a lysine residue modified with a glycine-glycine (diGly) moiety—is left at the site of ubiquitination [2]. This K-ε-GG remnant serves as a specific mass tag (a 114.04 Da mass shift on modified lysine residues) that can be detected by mass spectrometry (MS) [1] [2]. Although the ubiquitin-like proteins NEDD8 and ISG15 also generate an identical diGly remnant upon trypsin digestion, studies indicate that approximately 95% of identified diGly peptides originate from genuine ubiquitination events [2].

Analytical Workflows for diGly Peptide Analysis

The low stoichiometry of ubiquitination necessitates robust enrichment strategies prior to mass spectrometric analysis. The foundational workflow involves several critical steps: cell culture and lysis, protein digestion, peptide-level enrichment of diGly peptides, chromatographic fractionation, and finally, LC-MS/MS analysis [2].

A key advancement was the development of high-affinity antibodies specifically targeting the diGly remnant [2] [3] [4]. This antibody-based enrichment enables the isolation of endogenously modified peptides from complex biological mixtures without requiring genetic manipulation, making it applicable to clinical samples and animal tissues [1] [2]. The standard protocol often incorporates N-ethylmaleimide (NEM) in the lysis buffer to inhibit deubiquitinases and preserve the ubiquitination landscape [2].

To achieve greater analytical depth, chromatographic fractionation is employed prior to immunoenrichment. A highly effective strategy is basic reversed-phase (bRP) chromatography, which separates peptides based on hydrophobicity at high pH [3] [5]. This step reduces sample complexity and mitigates the issue of abundant ubiquitin-derived peptides overwhelming the enrichment capacity and MS detection [3]. For instance, pre-fractionating a tryptic digest into just three bRP fractions was shown to dramatically increase the number of identifiable diGly peptides [5].

Recent technological progress has shifted the acquisition mode in mass spectrometry from traditional Data-Dependent Acquisition (DDA) to Data-Independent Acquisition (DIA). DIA fragments all peptides within predefined mass windows simultaneously, leading to superior sensitivity, quantitative accuracy, and data completeness [3]. One study demonstrated that a DIA-based diGly workflow could identify approximately 35,000 distinct diGly peptides in a single measurement, doubling the identification count compared to DDA while also significantly improving quantitative reproducibility [3].

The diagram below illustrates the core workflow for diGly proteome analysis.

Key Methodological Optimizations and Data

Optimization of the liquid chromatography (LC) conditions is paramount for separating complex diGly peptide mixtures. The choice of acidic modifier in the mobile phase significantly impacts both chromatographic performance and MS detection sensitivity [6]. While trifluoroacetic acid (TFA) offers excellent peak resolution due to its strong ion-pairing properties, it causes significant signal suppression in electrospray ionization MS [6]. In contrast, formic acid (FA) provides superior MS sensitivity, albeit with potentially different selectivity and slightly broader peaks [6]. Balancing these factors is essential for method development.

The table below summarizes key achievements in diGly proteomics enabled by methodological optimizations.

Table 1: Key Methodological Optimizations in diGly Proteomics

Optimization	Key Achievement	Impact	Reference
Pre-fractionation (3 bRP fractions)	Enabled identification of >23,000 diGly peptides from HeLa cells.	Simplified, robust workflow for deep ubiquitinome coverage from cells and tissue (e.g., mouse brain).	[5]
DIA with tailored settings	Identified ~35,000 diGly sites in a single measurement; 45% of peptides had CV <20%.	Doubled identifications vs. DDA, with superior quantitative accuracy and reproducibility.	[3]
Deep Spectral Library	Compiled library of >90,000 diGly peptides from multiple cell lines and conditions.	Serves as a foundational resource for high-sensitivity DIA analyses of the ubiquitinome.	[3]

The application of these optimized workflows has generated vast datasets, providing quantitative insights into ubiquitination dynamics. For example, one landmark study quantitatively assessed the human "ubiquitinome," identifying approximately 19,000 diGly-modified lysine residues within about 5,000 proteins [4]. Quantitative diGly proteomics can also reveal dynamic changes in cellular signaling pathways. When applied to TNFα signaling, optimized workflows successfully captured known regulatory ubiquitination events while simultaneously uncovering a multitude of novel sites [3]. Furthermore, this approach has illuminated the extensive and dynamic nature of ubiquitination throughout the circadian cycle, uncovering hundreds of rhythmically modified sites on membrane receptors and transporters [3].

The Scientist's Toolkit: Essential Reagents and Materials

Successful diGly proteomics requires specific reagents and materials at each stage of the workflow. The following table details essential components.

Table 2: Research Reagent Solutions for diGly Proteomics

Item	Function / Description	Example / Key Note
diGLY Antibody	Immunoaffinity enrichment of K-ε-GG-modified peptides.	Monoclonal antibody specifically recognizing the diGly remnant; available commercially as PTMScan kits.	[2] [3] [4]
N-Ethylmaleimide (NEM)	Deubiquitinase (DUB) inhibitor.	Added fresh to lysis buffer to preserve the native ubiquitination state by preventing deubiquitination.	[2]
Stable Isotope Labels (SILAC)	For quantitative comparison of ubiquitination between samples.	Heavy Lysine (K8) and Heavy Arginine (R10) incorporated metabolically during cell culture.	[2]
Urea Lysis Buffer	Protein denaturation and extraction.	Typically 8M Urea, which effectively denatures proteins while being compatible with subsequent digestion.	[2]
Proteases (LysC, Trypsin)	Protein digestion to generate peptides.	Often used sequentially (LysC first, then trypsin) for efficient and specific digestion.	[2] [3]
Acidic Modifiers (FA, TFA)	Mobile phase additives for LC-MS.	FA offers better MS sensitivity; TFA provides sharper peaks and different selectivity.	[6]
C18 SepPak Cartridges	Peptide desalting and clean-up.	Used for sample preparation prior to enrichment or LC-MS analysis.	[2]

Detailed Protocol: diGly Peptide Enrichment and Analysis

This protocol outlines the core steps for enriching and analyzing diGly peptides from mammalian cells, incorporating key optimizations.

Cell Culture, Lysis, and Protein Digestion

• Cell Culture and Lysis:

  • Culture cells in appropriate media. For quantitative comparisons, use SILAC labeling with heavy and light amino acids [2].
  • To enhance the detection of proteasome-targeted ubiquitination, treat cells with a proteasome inhibitor like MG132 (e.g., 10 µM for 4 hours) [3].
  • Lyse cells in a Urea-based lysis buffer (e.g., 8 M Urea, 50 mM Tris-HCl pH 8, 150 mM NaCl) supplemented with protease inhibitors and 5 mM NEM to inhibit DUBs [2].
  • Clarify the lysate by centrifugation.

• Protein Digestion:

  • Reduce and alkylate cysteine residues.
  • Perform a two-step enzymatic digestion. First, use LysC (e.g., 1:100 enzyme-to-protein ratio) for 2-3 hours at 25°C. Then, dilute the urea concentration and digest with trypsin (e.g., 1:50 ratio) overnight at 25°C [2].
  • Acidify the peptide mixture to stop digestion and desalt the peptides using a C18 solid-phase extraction cartridge (e.g., Waters Sep-Pak) [2].

Peptide Pre-fractionation and diGly Enrichment

• Basic pH Reversed-Phase (bRP) Fractionation:

  • To achieve deep coverage, fractionate the desalted peptide sample using bRP chromatography [3] [5].
  • Separate peptides on a C18 column using a gradient of increasing acetonitrile in a volatile basic buffer (e.g., ammonium bicarbonate or ammonium formate, pH ~10).
  • For a significant depth-of-coverage boost with minimal complexity, pool the collected fractions into a small number of pools (e.g., 3-8) [3] [5]. For MG132-treated samples, it is beneficial to separate and isolate fractions containing the highly abundant K48-linked ubiquitin chain-derived diGly peptide to prevent it from dominating the subsequent enrichment [3].

• Immunoaffinity Enrichment of diGly Peptides:

  • Take an aliquot of the fractionated peptides (optimal input is typically 1 mg of peptide material) [3].
  • Use a specific amount of anti-diGly antibody (e.g., 31.25 µg from a commercial vial) for enrichment [3].
  • Incubate the peptide fraction with the antibody beads with gentle rocking for several hours at 4°C to capture diGly-modified peptides.
  • Wash the beads extensively with cold PBS or another suitable buffer to remove non-specifically bound peptides. The use of a filter plug can make this wash step more efficient and improve specificity [5].
  • Elute the bound diGly peptides from the antibody with a low-pH elution buffer (e.g., 0.1-0.5% TFA or formic acid) [2].

LC-MS/MS Analysis and Data Processing

• Liquid Chromatography and Mass Spectrometry:

  • Analyze the enriched diGly peptides using a nano-flow reversed-phase LC system coupled online to an Orbitrap mass spectrometer.
  • For the mobile phase, formic acid (0.1%) is generally preferred as the acidic modifier over TFA due to its minimal ion suppression effects, which maximize MS sensitivity [6].
  • Utilize a Data-Independent Acquisition (DIA) method tailored for diGly peptides. An optimized method may use ~46 variable windows and a high MS2 resolution (e.g., 30,000) to balance spectral quality and sequencing speed [3]. Injecting as little as 25% of the total enriched material can be sufficient for a high-quality analysis [3].

• Data Processing and Analysis:

  • Process the raw DIA data using specialized software (e.g., Spectronaut, DIA-NN, Skyline) [3].
  • Match the acquired spectra against a comprehensive spectral library of diGly peptides. This library can be generated in-house from DDA runs of fractionated samples or obtained from public repositories [3].
  • For quantification, normalize the data and perform statistical analysis to identify significantly regulated ubiquitination sites across experimental conditions.

The relationships between the core analytical steps and their key optimizations are summarized in the following diagram.

Why Fractionation is Essential for Deep Ubiquitinome Coverage

Protein ubiquitylation is a crucial post-translational modification (PTM) involved in regulating virtually all cellular processes, from protein degradation to cell signaling and circadian rhythms [7] [8]. The tryptic digestion of ubiquitylated proteins generates peptides containing a characteristic diglycine (diGly) remnant on the modified lysine residue, which serves as a signature for mass spectrometry (MS)-based detection [2] [5]. However, the low stoichiometry of ubiquitylation within the complex background of unmodified peptides presents a significant analytical challenge [7] [8]. Without effective enrichment and separation, low-abundance diGly peptides remain masked, severely limiting the depth of ubiquitinome analysis. This application note details why fractionation, particularly basic pH reversed-phase (bRP) chromatography, is an indispensable step for achieving comprehensive coverage of the ubiquitinome, framed within our broader research on optimal diGly peptide separation strategies.

The Imperative for Deep Ubiquitinome Coverage

The Analytical Challenge

The depth of ubiquitinome analysis is fundamentally constrained by sample complexity. The diGly-modified proteome exists within a vast excess of non-modified peptides. Antibody-based enrichment using anti-K-ɛ-GG antibodies efficiently isolates diGly peptides, but even after enrichment, the sample remains highly complex [7] [2]. Single-shot liquid chromatography-mass spectrometry (LC-MS/MS) analysis of enriched samples is often insufficient to achieve the depth required for systems-wide studies, typically identifying only a fraction of the present ubiquitylation sites [8].

The Impact of Fractionation on Depth of Analysis

Fractionation reduces sample complexity by separating peptides based on specific physicochemical properties prior to LC-MS/MS. This allows the mass spectrometer to spend more time analyzing low-abundance peptides, leading to a dramatic increase in identifications. Research demonstrates that offline fractionation of peptides prior to diGly enrichment significantly improves results. One study showed that crude pre-fractionation into only three fractions via high-pH reverse-phase chromatography enabled the identification of over 23,000 diGly peptides from HeLa cells [5]. For the deepest possible coverage, more extensive fractionation is employed. Another study fractionated peptides into 96 fractions, concatenated into 8-9 pools, which facilitated the creation of a spectral library containing over 90,000 diGly peptides—the deepest ubiquitinome to date [8].

Table 1: Quantitative Impact of Fractionation on Ubiquitinome Coverage

Fractionation Method	Number of Fractions	Sample Type	Identified DiGly Peptides	Key Improvement
None (Single-shot)	1	HEK293 cells (MG132 treated)	~35,000 [8]	Requires highly optimized DIA MS
bRP Fractionation	3	HeLa cells (MG132 treated)	>23,000 [5]	Simpler pre-fractionation
bRP Fractionation	8-9 (from 96)	HEK293 & U2OS cells (MG132 treated)	~90,000 (library) [8]	Deepest coverage for library building
High-pH RP HPLC	12	Immunodepleted Human Plasma	Greatest depth vs. other methods [9]	Superior for complex tissue samples

Basic pH Reversed-Phase Chromatography: The Orthogonal Fractionation Powerhouse

Principle and Rationale

Basic pH reversed-phase (bRP) chromatography separates peptides based on hydrophobicity at a pH of ~10. This makes it highly orthogonal to the standard acidic pH reverse-phase LC-MS/MS, which is the final separation step [9] [8]. Orthogonality is critical because it maximizes the separation of different peptides across fractions. bRP-HPLC has been systematically compared to other fractionation methods like 1-D SDS-PAGE and peptide isoelectrofocusing (OFFGEL electrophoresis) for profiling complex samples such as human plasma. It demonstrated the highest peptide resolution and yielded the best depth of analysis, detecting the largest number of known low-abundant proteins for a given level of fractionation [9].

Key Advantages for DiGly Peptides

DiGly peptides often have unique physicochemical properties. The modification itself can hinder tryptic cleavage, resulting in longer peptide sequences with higher charge states [8]. bRP chromatography effectively handles this diversity. Furthermore, the high resolution of bRP-HPLC can be leveraged to separate highly abundant ubiquitin-derived diGly peptides (e.g., the K48-linked chain peptide) from other less abundant cellular diGly peptides. Isolating these abundant peptides prevents them from dominating the MS signal and enables the detection of co-eluting, lower-abundance peptides, thereby increasing overall coverage [8].

Detailed Experimental Protocol for bRP Fractionation in Ubiquitinome Analysis

Sample Preparation Through Digestion

• Lysis: Lyse cells or tissue in a urea-based lysis buffer (e.g., 8 M Urea, 50 mM Tris-HCl, pH 8.0) supplemented with protease inhibitors and 5 mM N-Ethylmaleimide (NEM) to preserve ubiquitin linkages and inhibit deubiquitinases [2].
• Protein Digestion: Reduce, alkylate, and digest proteins. A typical protocol involves sequential digestion with LysC and trypsin enzymes to ensure complete cleavage [2] [8].
• Desalting: Desalt the resulting peptide mixture using a C18 solid-phase extraction cartridge (e.g., Sep-Pak) and dry under vacuum [2].

Basic pH Reversed-Phase Fractionation

• Reconstitution: Reconstitute the dried peptide pellet in 1 mL of 10 mM ammonium bicarbonate, pH 10.
• Column Equilibration: Equilibrate a C18 column (e.g., XBridge C18, 5 μm, 4.6 mm x 250 mm) with 5-10 column volumes of 100% solvent A (10 mM ammonium bicarbonate, pH 10).
• Sample Loading and Separation: Load the peptide sample onto the column. Separate peptides using a linear gradient of solvent B (90% acetonitrile, 10 mM ammonium bicarbonate, pH 10) from 5% to 35% over 60-90 minutes at a flow rate of 0.5-1.0 mL/min, collecting 1-minute fractions.
• Fraction Concatenation: Pool the collected fractions in a non-contiguous manner to maximize orthogonality. For example, for 96 fractions, pool every 9th fraction to create 9 super-fractions (e.g., 1, 10, 19...; 2, 11, 20...; etc.) [8]. For simpler protocols, pooling into 3 fractions is still highly effective [5].
• Drying: Dry the concatenated fractions under vacuum.

DiGly Peptide Enrichment and MS Analysis

• Enrichment: Reconstitute each dried fraction in immunoaffinity purification (IAP) buffer and enrich for diGly peptides using anti-K-ɛ-GG antibody beads according to the manufacturer's protocol (e.g., PTMScan Ubiquitin Remnant Motif Kit) [2] [8].
• Elution and Cleanup: Elute the bound diGly peptides and desalt using C18 StageTips or similar micro-columns.
• Mass Spectrometry Analysis: Analyze each fraction by LC-MS/MS using either Data-Dependent Acquisition (DDA) for library generation or Data-Independent Acquisition (DIA) for high-sensitivity quantification, which has been shown to identify over 35,000 diGly sites in single measurements [8].

The following workflow diagram illustrates the complete protocol from sample preparation to data analysis:

The Scientist's Toolkit: Essential Reagents and Materials

Table 2: Key Research Reagent Solutions for Ubiquitinome Analysis

Item	Function / Rationale	Example / Specification
Anti-K-ɛ-GG Antibody	Immunoaffinity enrichment of diGly-containing peptides; core of enrichment workflow.	PTMScan Ubiquitin Remnant Motif Kit [2] [8]
Basic pH RP Column	High-resolution fractionation of peptides prior to enrichment; improves depth.	C18 column, 5μm, 4.6mm x 250mm (e.g., XBridge) [9]
Mass Spectrometer	High-sensitivity detection and identification of diGly peptides.	Orbitrap-based instrument with HCD fragmentation [5]
Urea Lysis Buffer	Efficient protein denaturation and extraction while preserving PTMs.	8 M Urea, 50 mM Tris-HCl, pH 8 [2]
N-Ethylmaleimide (NEM)	Deubiquitinase (DUB) inhibitor; prevents loss of ubiquitylation during processing.	Add fresh to lysis buffer (e.g., 5 mM) [2]

Applications and Biological Insights Enabled by Fractionation

The enhanced depth provided by bRP fractionation has directly enabled significant biological discoveries across diverse fields.

• Circadian Biology: An in-depth, systems-wide investigation of ubiquitination across the circadian cycle uncovered hundreds of cycling ubiquitination sites and clusters within individual membrane protein receptors and transporters, revealing new connections between metabolism and circadian regulation [8].
• Cancer and Signaling Pathways: Applying deep ubiquitinome profiling to basal and luminal human breast cancer models has identified proteins modulated by ubiquitylation, providing insights into cancer progression and potential therapeutic targets [7]. Furthermore, comprehensive analysis of TNF signaling has captured known sites while adding many novel ones, expanding our understanding of this critical pathway [8].
• Neurological Research: The fractionation-enhanced workflow has proven applicable to complex in vivo samples, such as mouse brain tissue, enabling the in-depth analysis of the endogenous, unstimulated ubiquitinome in a therapeutically relevant context [5].

Troubleshooting and Protocol Optimization

• Low DiGly Peptide Yield: Ensure fresh DUB inhibitors (NEM) are used in the lysis buffer. Titrate the antibody-to-peptide input ratio; a starting point of 31.25 µg antibody per 1 mg of peptide material is often optimal [8].
• High Background in MS: Implement stringent wash steps after antibody enrichment. Using a filter plug to retain antibody beads during washes can reduce non-specific binding and increase specificity for diGly peptides [5].
• Incomplete Fractionation: Check the pH of the mobile phases for bRP chromatography; it must be ~10. Ensure the C18 column is properly equilibrated with the basic solvent before sample loading.

Fractionation is not merely an optional step but a foundational requirement for deep ubiquitinome coverage. Basic pH reversed-phase chromatography, in particular, serves as a powerful and orthogonal separation method that dramatically reduces sample complexity, allowing for the detection of thousands of otherwise masked low-abundance diGly peptides. By integrating robust bRP fractionation with sensitive MS analysis, researchers can achieve an unprecedented view of the ubiquitinome, driving discovery in basic biology, drug development, and translational research.

Core Principles of Basic pH Reversed-Phase Liquid Chromatography

Basic pH Reversed-Phase Liquid Chromatography (bRPLC) is a high-resolution separation technique where the mobile phase is maintained at a basic pH, typically between 8 and 10. This method leverages the fundamental principle of controlling the ionization state of analytes to alter their interaction with the hydrophobic stationary phase [10].

In bRPLC, the alkaline mobile phase environment suppresses the ionization of acidic functional groups and promotes the deprotonation of silanol groups on the silica-based stationary phase. This results in a distinctly different selectivity profile compared to traditional acidic pH separations [10] [11]. The retention mechanism is primarily governed by hydrophobic interactions, but with significantly reduced secondary interactions from charged surface silanols, leading to improved peak shapes and altered elution orders for basic and acidic compounds [12].

Advantages of Basic pH over Acidic pH Separations

The strategic use of basic pH conditions offers several chromatographic advantages for specific applications, particularly in complex proteomic analyses.

Enhanced Selectivity and Orthogonality

Basic pH conditions provide a complementary separation selectivity to acidic pH RPLC. This orthogonality is particularly valuable in two-dimensional separation systems, where it significantly increases peak capacity and improves the resolution of complex peptide mixtures [13] [14]. The different ionization states of peptides at high pH alter their hydrophobicity, resulting in elution profiles that are not merely reversed but fundamentally distinct from those obtained at low pH.

Improved Peak Shape for Basic Analytes

Under acidic pH conditions, basic analytes such as peptides with primary amines or basic amino acid residues can exhibit peak tailing due to undesirable ionic interactions with negatively charged residual silanol groups on the silica stationary phase [15] [11]. At basic pH, these silanol groups are deprotonated and less accessible for interaction, while many basic compounds are in their neutral form, thereby minimizing these adverse interactions and yielding sharper, more symmetrical peaks [10].

Optimal Performance for Specific Applications

The bRPLC approach has demonstrated exceptional utility in specialized applications, particularly in proteomics. When combined with tip-based strong cation exchange (SCX-Tip) in the ReST method, bRPLC enabled the identification of 43.6% more cross-linked peptides compared to conventional SCX approaches [13]. Similarly, in ubiquitinome studies, offline high-pH reverse-phase fractionation prior to diGly peptide enrichment proved crucial for the deep analysis of ubiquitination sites [16].

Reduction of Metal-Sensitive Analyte Adsorption

Modern bRPLC columns often feature inert hardware designed to minimize metal interactions [17]. This is particularly beneficial at basic pH where the risk of metal-catalyzed degradation or adsorption of metal-sensitive compounds is reduced, leading to improved analyte recovery and more accurate quantification [17].

Table 1: Comparative Analysis of bRPLC versus Acidic pH RPLC

Parameter	Basic pH RPLC	Acidic pH RPLC
Typical pH Range	8.0 - 10.0	2.0 - 4.0
Ionization of Silanols	Deprotonated, less accessible	Partially protonated, more interactive
Peak Shape for Basic Analytes	Sharper, more symmetrical	Often tailed due to silanol interactions
Selectivity	Orthogonal to acidic pH	Standard for most RPLC applications
Optimal Use Cases	Complex peptide mixtures, cross-linked peptide analysis, diGly peptide enrichment	General purpose separations, simple peptide maps
Compatibility with MS	Excellent with volatile basic buffers (e.g., ammonium formate)	Excellent with volatile acidic buffers (e.g., formic acid)

Table 2: Impact of pH on Analyte Retention and Separation

Analyte Type	Behavior at Acidic pH	Behavior at Basic pH
Acidic Compounds	Protonated (neutral); increased retention	Deprotonated (charged); decreased retention
Basic Compounds	Protonated (charged); strong silanol interactions	Neutral; reduced silanol interactions, better peak shape
Polar Basic Molecules	Poor retention on C18	Often better retained, especially in HILIC mode [12]

Experimental Protocols

Protocol 1: Micro-Scale bRPLC Fractionation for Limited Samples

This protocol adapts the bRPLC technique for processing small biological samples (5-20 μg), minimizing sample handling and transfer losses [14].

Materials:

• C18 StageTips (ThermoFisher Scientific, SP301)
• Jupiter C18 resin (5 μm particle diameter, Phenomenex)
• Ammonium bicarbonate (NH₄HCO₃), 100 mM, pH 8.0
• Acetonitrile (HPLC grade)
• Centrifuge capable of 3,000 × g

Procedure:

• Column Preparation: Create a slurry of 2 mg Jupiter C18 material in 1 mL acetonitrile. Add this slurry to a commercially produced C18 StageTip microcolumn [14].
• Column Conditioning: Centrifuge at 3,000 × g for 3 minutes for all elution steps. Wash the column with 100 μL of 100% acetonitrile, followed by 100 μL of equilibration buffer (100 mM NH₄HCO₃, pH 8.0) [14].
• Sample Loading: Apply the digested peptide mixture to the conditioned column and centrifuge.
• Step-Gradient Elution: Fractionate the sample using 100 μL portions of seven different elution buffers: 5%, 10%, 15%, 20%, 25%, 30%, and 90% acetonitrile in 100 mM NH₄HCO₃, pH 8.0. Collect each fraction separately by centrifugation [14].
• Sample Storage: Lyophilize all fractions to completeness and store at -20°C until LC-MS/MS analysis.

Protocol 2: Large-Scale Cross-Linked Peptide Analysis (ReST Method)

This two-dimensional strategy combines bRPLC fractionation with tip-based SCX (SCX-Tip) for large-scale cross-linked peptide analysis [13].

Materials:

• bRPLC Column: C18 column compatible with basic pH (e.g., compatible up to pH 12)
• SCX-Tip extraction tips
• Ammonium formate solution (pH 10.0)
• Acetonitrile (HPLC grade)
• Formic acid and other ion-pairing agents

Procedure:

• First Dimension - bRPLC Fractionation:
  • Set up a C18 column with mobile phase A (aqueous buffer at pH 10) and mobile phase B (acetonitrile).
  • Separate the peptide mixture using a shallow gradient from low to high organic solvent concentration.
  • Collect fractions at regular time intervals throughout the chromatographic run [13].

• Second Dimension - SCX-Tip Enrichment:

  • Acidify each bRPLC fraction to convert basic mobile phase to acidic conditions compatible with SCX.
  • Process each fraction through SCX-Tips according to manufacturer's instructions.
  • Elute bound peptides from SCX-Tips using a stepped salt gradient [13].

• Mass Spectrometry Analysis:

  • Pool and concentrate SCX eluents.
  • Analyze by LC-MS/MS using standard acidic pH reverse-phase nanoflow chromatography coupled to a high-resolution mass spectrometer.

Protocol 3: High-pH Reverse-Phase Fractionation for diGly Peptide Enrichment

This protocol describes the offline high-pH fractionation step used prior to immunoenrichment of diGly peptides for ubiquitinome analysis [16].

Materials:

• High-pH RP C18 Chromatography Column: Polymeric stationary phase material (300 Å, 50 μm)
• Empty 6 mL column cartridge
• Trifluoroacetic acid (TFA), 0.5%
• Ammonium formate solution (pH 10.0)
• Acetonitrile (HPLC grade)

Procedure:

• Sample Preparation: Digest ubiquitinated proteins using Lys-C and trypsin. Add TFA to a final concentration of 0.5% to precipitate and remove detergents. Centrifuge at 10,000 × g for 10 minutes and collect the supernatant [16].
• Column Packing: Prepare an empty 6 mL column cartridge filled with 0.5 g of stationary phase material for approximately 10 mg of protein digest (maintaining a 1:50 w/w protein digest to stationary phase ratio) [16].
• Sample Loading: Load the peptide mixture onto the prepared column.
• Column Washing: Wash the column with approximately 10 column volumes of 0.1% TFA, followed by 10 column volumes of H₂O.
• Peptide Elution: Elute the peptides into three fractions with 10 column volumes of 10 mM ammonium formate solution (pH 10) containing 7%, 13.5%, and 50% acetonitrile, respectively [16].
• Sample Concentration: Lyophilize all fractions to completeness before proceeding to diGly peptide immunoenrichment.

Workflow Visualization

bRPLC-SCX Workflow for Deep Proteomics

Research Reagent Solutions

Table 3: Essential Materials for bRPLC Experiments

Reagent/Material	Function/Application	Example Specifications
Basic-pH Stable C18 Column	Core separation media for bRPLC	High pH stability (pH 2-12); e.g., Halo 120 Å Elevate C18 [17]
Ammonium Bicarbonate (NH₄HCO₃)	Volatile buffer for mobile phase at basic pH	100 mM, pH 8.0; MS-compatible [14]
Ammonium Formate	Volatile buffer for higher pH mobile phases	10 mM, pH 10.0; MS-compatible [16]
C18 StageTips	Micro-scale fractionation devices	Jupiter C18 material (5 μm) [14]
SCX-Tips	Second-dimension enrichment for cross-linked peptides	Strong cation exchange tips [13]
Anti-K-ε-GG Antibody Beads	Immunoenrichment of diGly peptides	Agarose-conjugated for ubiquitination site mapping [16]
Inert HPLC Hardware	Minimizes metal interaction with sensitive analytes	Passivated surfaces for improved recovery [17]

Linking Chromatographic Resolution to Downstream MS Sensitivity and Proteome Depth

In bottom-up proteomics, the analysis of complex peptide mixtures derived from more than a million peptides across a concentration range exceeding six orders of magnitude presents a formidable analytical challenge [18]. The efficiency of initial peptide separation profoundly influences downstream mass spectrometry (MS) sensitivity and overall proteome depth, particularly for specialized applications like ubiquitinomics where modified peptides exist at low stoichiometry. This application note explores the critical relationship between chromatographic resolution and MS performance, with specific focus on basic pH reversed-phase chromatography (high-pH RP) for diGly peptide fractionation. We demonstrate how optimized separation strategies significantly enhance detection sensitivity, quantitative accuracy, and proteome coverage in ubiquitinome analyses.

The fundamental challenge in proteomics lies in the vast dynamic range of protein abundance, which is particularly extreme for post-translational modifications like ubiquitination. Even with modern high-duty cycle instruments, comprehensive analysis requires efficient fractionation to reduce sample complexity prior to LC-MS/MS analysis [19]. High-pH reversed-phase chromatography coupled with fraction concatenation has emerged as a powerful alternative to traditional strong-cation exchange (SCX) chromatography, offering improved separation orthogonality, reduced sample loss, and simplified processing [19].

The Chromatographic Foundation for MS Sensitivity

The Orthogonality Principle in 2D Separations

The effectiveness of two-dimensional liquid chromatography (2D-LC) depends on the compatibility of the two separations, their individual separation efficiencies, and critically, their orthogonality—the degree to which their separation mechanisms are uncorrelated [19]. When low pH reversed-phase LC is used as the second dimension (the most common configuration for MS compatibility), high-pH RPLC provides exceptional orthogonality as the first dimension. The orthogonality stems from altered peptide charge distribution at different pH values, which substantially changes retention behavior between the two dimensions [19].

Compared to SCX-RPLC, concatenated high-pH RPLC-low pH RPLC demonstrates more uniform coverage of the 2D separation space. While SCX provides theoretical orthogonality to RPLC, most tryptic peptides carry 2+, 3+ and 4+ charges and tend to group during SCX fractionation, leading to non-uniform use of the 2D space and reduced separation efficiency [19]. This fundamental limitation of SCX is overcome by the high-pH RP approach, which distributes peptides more evenly across the separation space.

The Concatenation Strategy for Enhanced Proteome Coverage

Fraction concatenation—pooling non-adjacent fractions from the first dimension separation—significantly improves orthogonality and proteome coverage in 2D RPLC-RPLC shotgun analyses [19]. This approach involves combining early, middle, and late RPLC fractions eluted over equal time intervals with minimal overlap into single concatenated fractions.

Table 1: Comparative Performance of Different 2D-LC Strategies in Proteome Analysis

Separation Method	Unique Peptides Identified	Unique Proteins Identified	Key Advantages
SCX - Low pH RPLC (Traditional)	~20,900	~2,727	Established method, good orthogonality
Concatenated High pH RPLC - Low pH RPLC	~37,633	~4,363	80% more peptides, 60% more proteins than SCX; better orthogonality, reduced sample loss
Low pH RPLC - Low pH RPLC with Concatenation	~2x increase vs non-concatenated	~2x increase vs non-concatenated	Improved utilization of second dimension separation

The practical implementation of concatenation requires careful consideration of the first dimension gradient time and the desired number of LC-MS/MS analyses. Optimal concatenation combines fractions with minimal overlap that spread across the entire elution profile, with species in each concatenated fraction eluting at least minutes apart to minimize overlap [19]. Longer gradients that more effectively resolve peptides in neighboring fractions reduce overlap between post-concatenation fractions, further enhancing separation efficiency.

Experimental Protocols

Protocol: High-pH Reversed-Phase Chromatography with Fraction Concatenation for diGly Peptide Analysis

Principle: This protocol describes the offline fractionation of complex peptide mixtures using high-pH reversed-phase chromatography with fraction concatenation to maximize orthogonality with subsequent low-pH RPLC-MS/MS analysis.

Materials:

• LC System: HPLC system capable of delivering high-precision gradients
• Column: C18 reversed-phase column (e.g., 2.1 × 150 mm, 3.5 μm particles)
• Mobile Phase A: 10 mM ammonium bicarbonate, pH 10 (or 0.1% ammonium hydroxide, pH ~10)
• Mobile Phase B: 10 mM ammonium bicarbonate in 90% acetonitrile, pH 10 (or 0.1% ammonium hydroxide in 90% ACN)
• Sample: Tryptic peptides (100-500 μg) from cell lysate or tissue

Procedure:

• Column Equilibration: Equilibrate the column with 2% mobile phase B at a flow rate of 0.2 mL/min for 15-20 column volumes.
• Sample Loading: Dissolve peptide sample in mobile phase A and load onto the column.
• Gradient Separation: Execute a linear gradient from 5% to 35% B over 60 minutes, followed by a increase to 80% B over 5 minutes for column cleaning.
• Fraction Collection: Collect 1-minute fractions (approximately 200 μL each) throughout the entire gradient elution.
• Fraction Concatenation: Pool fractions using a concatenation scheme where early, middle, and late eluting fractions are combined. For example, if collecting 60 fractions, pool fractions 1, 21, and 41; 2, 22, and 42; etc., to create 20 pooled fractions.
• Sample Concentration: Concentrate pooled fractions by vacuum centrifugation and reconstitute in 0.1% formic acid for subsequent LC-MS/MS analysis.

Notes:

• The high-pH mobile phase conditions enhance separation selectivity compared to low-pH RPLC.
• Concatenation significantly improves orthogonality with the second dimension low-pH separation.
• This approach eliminates the need for sample desalting between dimensions, reducing processing time and sample losses [19].

Protocol: diGly Peptide Enrichment for Ubiquitinome Analysis

Principle: This protocol describes the immunoaffinity enrichment of ubiquitin-derived diGly-containing peptides using a K-ε-GG remnant motif-specific antibody, enabling large-scale ubiquitinome analysis.

Materials:

• Lysis Buffer: 8 M urea, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, complete protease inhibitor, 1 mM NaF, 1 mM β-glycerophosphate, 1 mM NaV, 5 mM N-ethylmaleimide (NEM, prepared fresh) [2]
• Digestion Enzymes: LysC (Wako, 2 AU) and trypsin (Sigma, TPCK-treated)
• diGLY Antibody: PTMScan Ubiquitin Remnant Motif (K-ε-GG) Kit (Cell Signaling Technology) or equivalent
• Desalting: SepPak tC18 reverse phase columns (Waters)

Procedure:

• Cell Lysis and Protein Extraction: Lys cells in urea buffer supplemented with 5 mM NEM to preserve ubiquitination by inhibiting deubiquitinases.
• Protein Digestion: Reduce proteins with 1 mM DTT, alkylate, and digest first with LysC (1:50 w/w, 3h) followed by trypsin (1:50 w/w, overnight).
• Peptide Desalting: Desalt peptides using C18 SepPak columns according to manufacturer's instructions.
• diGly Peptide Enrichment: Incubate 1-2 mg of peptide material with 31.25 μg of anti-diGly antibody (1/8 vial) with rotation for 2 hours at 4°C [3].
• Immunoprecipitation: Add protein A/G agarose beads and incubate for an additional 30-60 minutes.
• Wash and Elute: Wash beads extensively with ice-cold PBS, then elute diGly peptides with 0.1% TFA.
• Sample Preparation for MS: Concentrate eluted peptides by StageTip or vacuum centrifugation.

Notes:

• NEM alkylation is critical to preserve ubiquitination sites by inhibiting deubiquitinating enzymes.
• Antibody and peptide input should be optimized; 1 mg peptide material with 31.25 μg antibody is typically optimal [3].
• Only 25% of the total enriched material may be needed for injection when using sensitive DIA methods [3].

Advanced MS Acquisition Strategies for Enhanced Sensitivity

Data-Independent Acquisition for diGly Proteomics

Data-independent acquisition (DIA) has emerged as a powerful alternative to data-dependent acquisition (DDA) for ubiquitinome analysis, offering improved data completeness, quantitative accuracy, and sensitivity [3]. In DIA, all co-eluting peptide ions within predefined m/z windows are fragmented and acquired simultaneously, unlike the intensity-based precursor selection of DDA.

Table 2: Performance Comparison of DDA vs. DIA in diGly Proteome Analysis

Parameter	Data-Dependent Acquisition (DDA)	Data-Independent Acquisition (DIA)
diGly Peptides in Single Run	~20,000	~35,000
Quantitative Reproducibility (CV <20%)	15% of peptides	45% of peptides
Quantitative Reproducibility (CV <50%)	~50% of peptides	77% of peptides
Total Distinct diGly Peptides (6 replicates)	24,000	48,000

For diGly proteomics specifically, DIA method settings require optimization due to the unique characteristics of diGly peptides. Impeded C-terminal cleavage of modified lysine residues frequently generates longer peptides with higher charge states [3]. Optimal DIA methods for diGly analysis employ:

• 46 precursor isolation windows
• High MS2 resolution (30,000)
• Customized window placement based on empirical precursor distributions

This optimized DIA approach increases diGly peptide identifications by approximately 13% compared to standard full proteome DIA methods [3].

Prioritized Acquisition for Targeted Sensitivity

Prioritized Single-Cell ProtEomics (pSCoPE) represents an innovative acquisition strategy that increases proteome coverage, data completeness, and dynamic range by replacing the standard "topN" precursor selection heuristic with a priority-based system [20]. This method:

• Maximizes instrument time spent analyzing identifiable peptides
• Consistently analyzes thousands of prioritized peptides across all single cells
• Increases the number of quantified proteins per single cell by 106%
• Expands the dynamic range of quantified proteins, enabling detection of lower-abundance species

The median precursor intensity of peptides quantified by pSCoPE is 2.5-fold lower than with shotgun analysis, demonstrating significantly enhanced sensitivity for low-abundance peptides [20].

Workflow Visualization

Diagram 1: Integrated Workflow Linking Chromatography to MS Sensitivity. This workflow illustrates how high-pH RPLC fractionation with concatenation directly enables enhanced MS sensitivity and proteome depth through improved sample preparation and advanced acquisition strategies.

Diagram 2: Mechanism of Chromatographic Impact on MS Sensitivity. This diagram illustrates the causal relationships through which high chromatographic resolution enhances MS sensitivity, including reduced complexity, improved ionization efficiency, enhanced ion transmission, and reduced matrix effects.

Research Reagent Solutions

Table 3: Essential Research Reagents for diGly Proteomics

Reagent / Kit	Manufacturer	Function	Application Notes
PTMScan Ubiquitin Remnant Motif Kit	Cell Signaling Technology	Immunoaffinity enrichment of diGly peptides	Critical for ubiquitinome studies; specifically recognizes K-ε-GG remnant after trypsin digestion
LysC Protease	Wako	Protein digestion with high specificity	Cleaves C-terminal to Lys; reduces missed cleavages near modified lysines
SepPak tC18 Columns	Waters	Peptide desalting and concentration	500mg cartridges recommended for 30mg protein digest; essential for clean MS spectra
N-Ethylmaleimide (NEM)	Various	Deubiquitinase inhibition	Preserves ubiquitination sites; add fresh to lysis buffer at 5mM concentration
SILAC Amino Acids (K8, R10)	Cambridge Isotope Labs	Metabolic labeling for quantification	Enables accurate relative quantification between samples; K8: 13C6,15N2; R10: 13C6,15N4
High-pH Stable C18 Columns	Various	Peptide fractionation	Enable high-pH RPLC separation; 2.1 × 150mm, 3.5μm particles typical

The strategic integration of high-resolution chromatographic separations with optimized MS acquisition methods creates a powerful framework for enhancing sensitivity and proteome depth in ubiquitinome analyses. High-pH reversed-phase chromatography with fraction concatenation provides superior orthogonality to low-pH RPLC-MS/MS compared to traditional SCX approaches, enabling significantly increased identifications of diGly peptides and proteins. When combined with advanced acquisition strategies like DIA and prioritized analysis, these separation techniques dramatically improve quantitative accuracy, data completeness, and detection of low-abundance ubiquitination events. The protocols and strategies outlined herein provide researchers with a comprehensive toolkit for maximizing analytical sensitivity in demanding proteomic applications, particularly for the systematic investigation of ubiquitin signaling at a systems-wide scale.

A Step-by-Step Protocol for High-Resolution diGly Peptide Fractionation using bRPLC

In the realm of proteomic research, the efficacy of analytical separations hinges critically on the selection of an appropriate stationary phase. This is particularly true for basic pH reversed-phase chromatography, which has emerged as a powerful first-dimension separation technique in two-dimensional liquid chromatography (2D-LC) workflows for shotgun proteomics. The selection process involves a nuanced understanding of three interconnected pillars: particle technology (the physical architecture of the packing material), pore size (which governs accessibility to the retentive surface), and ligand chemistry (the specific hydrophobic moieties bonded to the silica surface). When optimized, this trifecta provides the orthogonality, resolution, and peak capacity necessary to resolve complex peptide mixtures, such as those containing ubiquitin-derived diGly remnants, prior to tandem mass spectrometric analysis. This application note delineates the key considerations for stationary phase selection within the context of a broader thesis on basic pH reversed-phase chromatography for diGly peptide fractionation, providing researchers with detailed protocols and data-driven guidance for method development.

The Scientist's Toolkit: Research Reagent Solutions

The table below catalogs essential materials and their functions for developing robust basic pH reversed-phase separations for diGly peptide analysis.

Table 1: Key Research Reagents and Materials for Basic pH Reversed-Phase Chromatography

Item	Function/Description	Application Note
Superficially Porous Particles (SPP)	Particles with a solid core and a porous shell; enhance mass transfer kinetics.	Superior efficiency compared to fully porous particles, especially for larger biomolecules [21].
High-pH Stable C18/Ligand	Reversed-phase ligand chemically bonded to silica with enhanced stability at pH > 9.	Provides the hydrophobic interaction mechanism for peptide separation at high pH [19].
Ammonium Hydroxide (NH₄OH)	High-purity source for mobile phase pH adjustment.	A common, volatile additive for creating basic mobile phases (e.g., pH 10) that are MS-compatible [19].
Ammonium Formate/Bicarbonate	Volatile buffering salts for pH control.	Used to prepare buffers that maintain a stable basic pH and are compatible with mass spectrometry [19].
Acetonitrile (HPLC Grade)	Strong organic solvent for reversed-phase gradient elution.	The preferred organic modifier due to its low viscosity and strong eluting power in high-pH RPLC [22].
Anti-diGly Antibody	Immunoaffinity enrichment reagent for ubiquitinated peptides.	Critical for isolating low-abundance diGly-modified peptides from complex digests prior to fractionation [3].

Particle Technology and Pore Size Fundamentals

Particle Architecture: Fully Porous vs. Superficially Porous

The physical structure of chromatographic particles is a primary determinant of column efficiency. While fully porous particles (FPP) provide substantial surface area for retention, they can suffer from enhanced resistance to mass transfer, particularly for larger molecules. Superficially porous particles (SPP), also known as core-shell particles, feature a solid, non-porous core surrounded by a thin, porous shell. This architecture drastically shortens the diffusion path for analytes, minimizing band broadening and leading to higher chromatographic efficiency, especially when operating above optimal flow rates [21]. For high-resolution separations of complex peptide mixtures, SPPs are often the material of choice due to their superior kinetic performance.

The Critical Role of Pore Size

Pore size selection is frequently overlooked but is paramount for achieving optimal retention and recovery. The pore diameter must be sufficiently large to permit unrestricted access of the analyte to the vast internal surface area where retention occurs.

• Small Molecules (e.g., pharmaceuticals, metabolites): For analytes like lorazepam (321 Da), retention is greater on smaller pore materials (e.g., 90 Å) because the molecule can access the higher surface area these particles provide. Performance in terms of efficiency is nearly identical between 90 Å and 160 Å SPPs for such small molecules [21] [23].
• Peptides and Mid-size Biomolecules: As analyte size increases, restricted diffusion into smaller pores becomes significant. A dramatic inversion of retention behavior is observed. For instance, insulin (5777 Da) shows significantly greater retention on 160 Å SPPs compared to 90 Å SPPs, as its access to the stationary phase within the smaller pores is hindered [21] [23]. A general guideline is that the pore diameter should be at least 4-10 times the analyte's hydrodynamic diameter to prevent restricted access and loss of retention [21].
• diGly Peptide Considerations: Ubiquitin-derived diGly peptides, the focus of ubiquitinome studies, often have impaired C-terminal cleavage at the modified lysine, resulting in longer peptides with higher charge states [3]. This increased size necessitates the use of larger pore stationary phases (e.g., 160 Å or larger) to ensure full access to the retentive surface and maximize recovery.

Table 2: Effect of Pore Size on Retention and Application Suitability

Analyte (Molecular Weight)	Retention on 90 Å SPP	Retention on 160 Å SPP	Recommended Application
Lorazepam (321 Da)	Higher retention	Lower retention	Small molecule pharmaceuticals
Insulin Chain B (3496 Da)	Similar retention	Similar retention	Transition point for pore selection
Insulin (5777 Da)	Lower retention	Higher retention	Medium-to-large peptide separation
diGly-Modified Peptides	Potential retention loss	Full retention capability	Ubiquitinome analysis [3]
Monoclonal Antibodies	Fully excluded	Fully excluded	Requires very large pores (e.g., 1000 Å) [21]

The following decision workflow visualizes the process of selecting the appropriate particle technology and pore size based on the analytical goal and analyte properties:

Diagram 1: A workflow for selecting particle technology and pore size based on analytical goals.

Ligand Chemistry and Mobile Phase Considerations

Ligand Selectivity and Stability

The chemical nature of the bonded phase is a powerful tool for manipulating selectivity. While C18 remains the most ubiquitous ligand for reversed-phase chromatography, alternative ligands such as phenyl-hexyl and C8 offer distinct selectivity for specific compound classes. The phenyl-hexyl phase, for example, can provide different selectivity through π-π interactions with analytes containing aromatic rings [21] [23]. For high-pH operation, the paramount consideration is the chemical stability of the bonded phase. Standard silica-based C18 columns can degrade at pH > 8. Therefore, it is essential to select columns specifically engineered for high-pH stability, often incorporating hybrid silica or specially bonded phases that resist hydrolysis and phase loss.

Mobile Phase Design for Basic pH Separations

The mobile phase is not merely a carrier but an active component that controls retention, selectivity, and MS-compatibility.

• pH and Buffer Selection: Operating at high pH (typically pH 10) alters the charge state of peptides, changing their interaction with the stationary phase and providing orthogonality to subsequent low-pH RPLC-MS/MS analysis [19]. Volatile basic additives like ammonium hydroxide or ammonium bicarbonate (e.g., 10-20 mM, pH 10) are ideal as they provide adequate buffering capacity and are fully compatible with mass spectrometry after fractionation [19] [22].
• Organic Modifier: Acetonitrile is the preferred strong solvent due to its low viscosity, favorable UV transparency, and strong eluting power, which collectively contribute to high efficiency and sharp peaks [22].
• Practical Advantage: A key benefit of high-pH RPLC is its tolerance for samples containing salts or urea, often eliminating the need for a desalting step prior to fractionation. This streamlines sample preparation and reduces sample losses, a critical advantage when working with precious clinical or biopsy samples [19].

Experimental Protocol: Basic pH Reversed-Phase Fractionation of diGly Peptides

This protocol is adapted from methodologies demonstrated to significantly enhance peptide and protein identifications in shotgun proteomics [19] [3].

Materials and Equipment

• HPLC System: Capable of generating high-pH mobile phases and performing precise gradients.
• Column: High-pH stable C18 column, 2.1 mm i.d. x 150 mm length, packed with 2.7 μm SPPs with 160 Å pores.
• Mobile Phase A: 10 mM Ammonium Bicarbonate, pH 10.0 (adjust with ammonium hydroxide).
• Mobile Phase B: 90% Acetonitrile / 10% 10 mM Ammonium Bicarbonate, pH 10.0.
• Sample: diGly-enriched peptides from a tryptic digest, dissolved in Mobile Phase A.

Step-by-Step Procedure

• System Equilibration: Equilibrate the column with 5% Mobile Phase B at a flow rate of 0.2 mL/min for at least 10 column volumes until a stable baseline is achieved.
• Sample Injection: Inject the diGly-enriched peptide sample (e.g., 1-10 μg total peptide mass).
• Gradient Elution: Execute a linear gradient from 5% to 40% Mobile Phase B over 60 minutes, followed by a ramp to 95% B over 5 minutes for a wash step.
• Fraction Collection: From the start of the gradient, collect 60 fractions at regular intervals (e.g., one fraction per minute) into a 96-well plate.
• Fraction Concatenation: Pool the 60 fractions into a reduced number of fractions (e.g., 10-15) using a concatenation scheme. For example, to create 10 final fractions, combine fractions 1, 11, 21, 31, 41, and 51 into Fraction 1; combine fractions 2, 12, 22, 32, 42, and 52 into Fraction 2; and so on. This strategy compensates for imperfect orthogonality and spreads the peptide content of each final fraction across the entire elution window of the subsequent low-pH analysis [19].
• Sample Storage and Analysis: Lyophilize the concatenated fractions and reconstitute them in a low-pH mobile phase (e.g., 0.1% formic acid) for LC-MS/MS analysis.

The overall workflow, from sample preparation to data analysis, is summarized below:

Diagram 2: The complete experimental workflow for 2D-LC analysis of diGly peptides.

Expected Results and Performance Metrics

When implemented correctly, the concatenated high-pH RPLC approach provides a dramatic improvement over traditional strong cation exchange (SCX) methods. In a direct comparison, this methodology yielded 37,633 unique peptides and 4,363 unique proteins from a tryptic digest of human cells, representing an increase of approximately 80% more peptides and 60% more protein identifications than obtained using SCX-RPLC [19]. The orthogonality offered by the high-pH/low-pH RPLC combination results in a much more uniform usage of the two-dimensional separation space, which is the foundation for this enhanced performance [19]. The reduced sample handling also minimizes losses, which is crucial for the analysis of low-abundance diGly peptides from limited biological samples.

In the context of basic pH reversed-phase chromatography for diGly peptide fractionation research, mobile phase optimization is a critical determinant for achieving high-resolution separations, maximal mass spectrometric response, and reproducible results. The analysis of post-translational modifications, particularly ubiquitination via diGly remnant enrichment, presents unique challenges due to the low stoichiometry of the modification and the complex nature of peptide mixtures [3]. This application note details optimized strategies for mobile phase preparation, focusing on the interrelated effects of buffer composition, pH precision, and organic modifier selection. These parameters collectively influence retention behavior, selectivity, and detection sensitivity in liquid chromatography-mass spectrometry (LC-MS) workflows, ultimately determining the depth of proteome coverage achievable in ubiquitinome studies [6] [3].

Materials and Methods

Research Reagent Solutions

The following table catalogues essential reagents and materials critical for reproducible mobile phase preparation and diGly peptide analysis.

Table 1: Essential Research Reagents for Mobile Phase Optimization and diGly Peptide Analysis

Reagent/Material	Function/Application	Key Considerations
Ammonium Formate/Acetate	Volatile buffer salt for pH control in LC-MS [24]	Provides buffering capacity; preferred for MS-compatibility to avoid source contamination.
Formic Acid (FA)	Acidic modifier for low-pH mobile phases [6] [24]	Provides low UV background and good ESI-MS response; weaker ion-pairing agent than TFA.
Trifluoroacetic Acid (TFA)	Strong ion-pairing acidic modifier [25] [6]	Excellent for chromatographic peak shape but causes significant ESI-MS signal suppression.
Acetonitrile (ACN)	Organic modifier for reversed-phase chromatography [25] [26]	Possesses dipole-dipole interaction properties; typically yields sharper peaks and lower backpressure.
Methanol (MeOH)	Alternative organic modifier [25] [26]	More acidic properties; can improve detection limits for certain peptide analyses and alter selectivity.
Anti-diGly Antibody	Immunoaffinity enrichment of ubiquitinated peptides [3]	Critical for isolating low-abundance diGly peptides from complex digests prior to LC-MS analysis.
Type-B Silica C18 Column	Stationary phase for reversed-phase separation [24]	High-purity silica with minimal acidic silanols, suitable for a pH range of 2-8.

Mobile Phase Preparation Protocol

Buffer and Acidic Modifier Selection

The choice of additive is dictated by the desired pH and detection method. For LC-MS workflows, volatile additives are mandatory.

• Low-pH Mobile Phase (pH ~2.5-3.0): Prepare 0.1% (v/v) formic acid in both aqueous and organic eluents. For increased buffering capacity, use 5-20 mM ammonium formate, pH-adjusted with formic acid [24].
• High-pH Mobile Phase (pH ~6.8-8.0): Prepare 5-20 mM ammonium bicarbonate or ammonium acetate, pH-adjusted with ammonium hydroxide [24]. Note that standard silica columns are less stable at higher pH.
• Ion-Pairing Modifier: For applications prioritizing peak shape over MS sensitivity, 0.05-0.1% (v/v) TFA can be used [6].

pH Measurement and Adjustment

Accurate pH measurement is non-trivial in aqueous-organic mixtures. The following protocol ensures consistency:

• Standard Aqueous pH Measurement: Measure the pH of the aqueous buffer component before adding the organic modifier. This is the most reproducible approach for routine analysis [27].
• Unified pH (wabspH) for Advanced Applications: For rigorous comparability between mobile phases of different organic compositions, employ the unified pH (wabspH) method based on the absolute chemical potential of the proton, as characterized by differential potentiometry with specialized salt bridges [27].
• Calibration: Calibrate the pH meter using standard aqueous buffers. For wabspH measurements, a specialized calibration against a standard pH 7.00 aqueous buffer is required [27].

Experimental Optimization Workflow

The systematic optimization of mobile phase conditions for diGly peptide fractionation involves an iterative process of parameter adjustment and evaluation, as outlined below.

Results and Discussion

Impact of Organic Modifier on Selectivity and Sensitivity

The choice of organic modifier (acetonitrile vs. methanol) is a powerful tool for manipulating selectivity and improving detection limits. These solvents interact differently with analytes and the stationary phase due to their distinct solvatochromic properties: methanol is more acidic, acetonitrile engages in dipole-dipole interactions, and tetrahydrofuran is more basic [25].

Table 2: Comparative Performance of Acetonitrile and Methanol in Peptide Analysis

Parameter	Acetonitrile (ACN)	Methanol (MeOH)
Primary Interaction	Dipole-dipole [25]	Proton donor/dipole [25]
Typical Backpressure	Lower	Higher
Gradient Time	Longer for equivalent separation	Shorter gradient times possible [26]
MS Sensitivity	Good	Superior; attomole-level detection achieved [26]
Protein ID Success	Lower in complex samples (e.g., 2D-GE digests)	Higher (100% success rate in one study) [26]
Selectivity Impact	Alters elution order relative to MeOH	Can resolve peptides co-eluting with ACN [25] [26]

The data demonstrates that methanol can serve as an excellent alternative to acetonitrile, offering the potential for higher sensitivity and faster analysis times in nanoLC-ESI-MS/MS workflows [26]. Switching between these solvents is a recommended strategy for investigating selectivity options during method development [25].

Influence of Acidic Modifier and pH on Retention and MS Response

For ionizable analytes like peptides, mobile phase pH is a critical parameter that controls ionization state, retention, and selectivity. The rule of thumb is to set the mobile phase pH at least 1.5 units away from the pKa of the analyte for robust retention control [24]. In the context of diGly peptide analysis, the acidic modifier choice creates a balance between chromatographic performance and MS detection.

Table 3: Effects of Formic Acid and Trifluoroacetic Acid on Peptide Separations

Characteristic	Formic Acid (FA)	Trifluoroacetic Acid (TFA)
Ion-Pairing Strength	Weak	Strong
Typical Peak Width	Broader	Narrower (more concentrated peaks) [6]
Peak Retention	Lower	Increased retention [6]
ESI-MS Signal	High	Significant suppression (~9-fold) [6]
Selectivity	Distinct elution profile	Alters elution order relative to FA [6]
Recommended Use	Standard for LC-MS where sensitivity is key	LC-UV or when improved peak shape is paramount [6]

The data indicates that while TFA improves chromatographic peak shape and retention, its strong ion-pairing nature and profound MS signal suppression make it less desirable for sensitive LC-MS work [6]. Formic acid is generally preferred, though its concentration and potential mixture with other volatile acids (e.g., acetic acid) can be optimized to fine-tune selectivity and sensitivity.

Buffer Concentration and Its Role in Separation Fidelity

Buffers are essential to resist pH changes that lead to irreproducible retention and selectivity [25]. Key considerations include:

• Buffer Capacity: A buffer's capacity is optimal when its pKa is within ±1.0 unit of the desired mobile-phase pH. Outside this range, buffering becomes ineffective [24].
• Concentration: Buffers with concentrations below 10 mM have little capacity, while concentrations above 50 mM risk precipitation when mixed with organic solvents [25]. A common effective range is 10-20 mM.
• Ionic Strength Effects: Increasing buffer concentration (ionic strength) can mask residual silanol activity on silica-based stationary phases, improving the peak shape of basic analytes [24]. This was demonstrated in an experiment where increasing phosphate buffer concentration from 1 mM to 10 mM at pH 2.5 dramatically improved the peak shape of 4-hexylaniline, a primary amine [24].

The optimization of mobile phase parameters—buffer composition, pH, and organic modifier—is a foundational step in developing robust and sensitive methods for basic pH reversed-phase chromatography of diGly peptides. The interplay of these parameters dictates the success of fractionation strategies aimed at deep ubiquitinome coverage. By applying the protocols and data-driven selection criteria outlined in this application note, researchers can systematically navigate the complex optimization landscape. This approach enables the attainment of high-resolution separations with maximal MS compatibility, which is essential for uncovering novel biological insights through ubiquitinome analysis.

In-depth proteome sequencing requires effective strategies to manage sample complexity, and fractionation is a critical step to achieve this goal. Within the study of ubiquitin signaling, the isolation of peptides with a signature diGly remnant is particularly important. This application note details advanced fractionation strategies, framed within a broader thesis on basic pH reversed-phase chromatography for diGly peptide research. We present a comparison of data acquisition methods, a detailed protocol for a high-coverage diGly proteomics workflow, and essential tools for researchers. The methods described herein are designed to enable researchers to deeply and accurately profile the ubiquitinome, supporting drug discovery and systems biology studies.

Data-Independent Acquisition for Superior DiGly Proteome Coverage

Mass spectrometry analysis of enriched diGly peptides presents challenges related to the low stoichiometry of the modification. Traditionally, Data-Dependent Acquisition (DDA) has been used, but this can result in limited coverage and quantitative accuracy. Data-Independent Acquisition (DIA) has emerged as a powerful alternative, offering improved sensitivity and reproducibility for PTM analysis.

Table 1: Performance Comparison of DDA vs. DIA for DiGly Proteome Analysis [28]

Parameter	Data-Dependent Acquisition (DDA)	Data-Independent Acquisition (DIA)
Distinct DiGly Peptides Identified (single run)	~20,000	~35,000
Quantitative Reproducibility (CV < 20%)	15% of peptides	45% of peptides
Overall Peptides Identified (across 6 runs)	~24,000	~48,000
Key Advantage	Established method	Superior depth, accuracy, and data completeness

The implementation of a DIA method, specifically optimized for the unique characteristics of diGly peptides (e.g., longer length and higher charge states), can more than double the number of identifications in a single measurement compared to DDA [28]. Furthermore, the quantitative accuracy is significantly enhanced, with a much larger proportion of peptides exhibiting low coefficients of variation.

Detailed Protocol: High-Coverage DiGly Peptide Analysis via bRP Fractionation and DIA

This protocol describes a workflow for deep ubiquitinome analysis, from cell culture to data acquisition, utilizing basic reversed-phase (bRP) fractionation to build a comprehensive spectral library followed by single-shot DIA analysis for high-throughput applications [28].

Materials and Reagents

• Cell Line: HEK293 or U2OS cells.
• Proteasome Inhibitor: MG132 (e.g., 10 µM treatment for 4 hours).
• Lysis Buffer: Standard urea- or detergent-based buffer for protein extraction.
• Digestion Enzymes: Trypsin and/or Lys-C.
• DiGly Enrichment Kit: Anti-K-ε-GG antibody-based enrichment kit (e.g., PTMScan Ubiquitin Remnant Motif Kit) [28] [29].
• bRP Chromatography System: HPLC system capable of high-pH stable separations.
• bRP Solvents: Solvent A (e.g., 10 mM triethylamine, pH 10), Solvent B (e.g., acetonitrile).
• Mass Spectrometer: Orbitrap-based mass spectrometer capable of DIA.

Procedure

Step 1: Sample Preparation and Digestion

• Culture cells and treat according to experimental design (e.g., with MG132 to enrich for ubiquitinated proteins).
• Harvest cells and extract proteins using a suitable lysis buffer.
• Reduce, alkylate, and digest the proteins using trypsin/Lys-C to generate peptides.
• Desalt the resulting peptide mixture.

Step 2: Basic Reversed-Phase (bRP) Fractionation for Library Generation

• Reconstitute a large amount of peptide (e.g., from 1-5 mg protein digest) in bRP Solvent A.
• Separate the peptides using a C18 column on an HPLC system with a shallow gradient of increasing Solvent B (e.g., 5-35% over 60 minutes) at basic pH (pH 10).
• Collect 96 fractions automatically [28].
• Employ Smart Concatenation: To reduce sample complexity and analysis time without sacrificing coverage, pool the 96 fractions non-adjacently into a smaller number of pools (e.g., 8 or 12). A recommended scheme is to pool fractions 1, 9, 17, 25... into pool 1; fractions 2, 10, 18, 26... into pool 2, and so on. This ensures peptides with widely different hydrophobicities are combined.
• Critical Note: The highly abundant K48-linked ubiquitin-chain derived diGly peptide should be isolated and processed separately to prevent it from dominating the enrichment and masking co-eluting peptides [28].
• Lyophilize the concatenated fractions.

Step 3: DiGly Peptide Immunoaffinity Enrichment

• Reconstitute each peptide fraction in immunoaffinity purification (IAP) buffer.
• Incubate the peptides with anti-diGly remnant antibody conjugated to beads. The antibody specifically binds the diGly motif left on lysine residues after tryptic digestion of ubiquitinated proteins [28] [29].
• Wash the beads thoroughly to remove non-specifically bound peptides.
• Elute the bound diGly peptides using a low-pH solution.
• Desalt the eluted peptides prior to MS analysis.

Step 4: Mass Spectrometric Analysis

• Spectral Library Generation: Analyze each of the 8-12 enriched fractions from Step 2 using a standard DDA method on the mass spectrometer. This compiles a deep, project-specific spectral library.
• Single-Shot DIA Analysis: For routine analysis of experimental samples, perform diGly enrichment on a smaller amount of peptide input (e.g., 1 mg). Inject a fraction of the enriched material and analyze using the optimized DIA method. This method should use narrow isolation windows and high MS2 resolution tailored to diGly peptides [28].
• Process the DIA data using the previously generated spectral library for peptide identification and quantification.

Diagram 1: High-coverage diGly proteome analysis workflow.

The Scientist's Toolkit: Key Research Reagent Solutions

Successful implementation of advanced fractionation strategies relies on specific, high-quality reagents and kits. The following table details essential solutions for diGly peptide research.

Table 2: Essential Research Reagents for DiGly Peptide Fractionation [30] [28] [29]

Research Reagent	Function & Application	Key Characteristics
Anti-K-ε-GG Antibody Kit	Immunoaffinity enrichment of ubiquitin-derived diGly peptides from complex digests.	High specificity for the diGly remnant; critical for reducing sample complexity prior to LC-MS/MS.
High pH Reversed-Phase Peptide Fractionation Kit	Orthogonal peptide fractionation based on hydrophobicity at high pH.	Proprietary pH-resistant resin in spin-column format; improves protein IDs by ≥50%; eliminates need for desalting.
Triethylamine (TEA) Buffer	Mobile phase for basic reversed-phase (bRP) chromatography.	Provides stable high-pH (e.g., pH 10) conditions for effective peptide separation orthogonal to low-pH LC-MS.
Pierce Peptide Desalting Spin Columns	Removal of salts and contaminants from peptide samples before or after fractionation.	Used for clean-up when the full fractionation kit is not required; compatible with small sample amounts.

The combination of deep spectral libraries generated from 96-fraction bRP chromatography with smart concatenation, and the subsequent use of optimized DIA methods, represents a powerful advanced strategy for ubiquitinome analysis. This workflow enables unprecedented depth of coverage and quantitative accuracy in single-run measurements, moving the field beyond the limitations of traditional DDA. By providing detailed protocols and key reagent information, this application note equips researchers to implement these robust methods, thereby accelerating discoveries in ubiquitin signaling and drug development.

Protein ubiquitination is a crucial post-translational modification (PTM) involved in virtually all cellular processes, from protein degradation to signal transduction and circadian regulation [8] [1]. The study of ubiquitination has been revolutionized by mass spectrometry (MS)-based proteomics, specifically through the detection of the characteristic diglycine (diGly) remnant left on modified lysine residues after tryptic digestion [2] [16]. However, the low stoichiometry of ubiquitination and sample complexity present significant challenges for comprehensive ubiquitinome analysis.

Basic pH reversed-phase liquid chromatography (bRPLC) has emerged as a powerful fractionation technique that addresses these challenges. This case study details how integrating bRPLC fractionation prior to diGly peptide enrichment enabled the creation of extensive spectral libraries containing over 90,000 diGly peptides and facilitated the identification of more than 35,000 distinct diGly peptides in single measurements [8]. We demonstrate the application of this optimized workflow across various biological contexts, including cell lysates and tissues.

Technical Advances in diGly Proteomics

The Critical Role of bRPLC Fractionation

The depth of ubiquitinome coverage achieved in this study relied heavily on an optimized bRPLC fractionation strategy applied prior to immunoenrichment of diGly peptides. The conventional single-enrichment approach is limited by sample complexity and dynamic range issues, where highly abundant peptides compete for antibody binding sites [8] [5].

The implemented workflow incorporated several key improvements:

• High-resolution fractionation: Tryptic peptides from MG132-treated cells were separated by bRPLC into 96 fractions using a C18 column with polymeric stationary phase material (300 Å, 50 µM) [8] [16].
• Strategic pooling: These fractions were concatenated into 8 primary pools, with the highly abundant K48-linked ubiquitin-chain derived diGly peptide processed separately to prevent competition during enrichment [8].
• Enhanced specificity: This pre-fractionation reduced sample complexity, allowing for more efficient antibody binding and significantly increasing the number of identifiable diGly peptides [5] [16].

Additional protocol refinements included filter-based cleanup to retain antibody beads more efficiently and optimized peptide fragmentation settings in the Orbitrap HCD cell, collectively contributing to superior performance [5] [16].

Workflow Optimization and Data Acquisition

The integration of bRPLC with subsequent diGly peptide enrichment and advanced mass spectrometry created a robust pipeline for deep ubiquitinome analysis, as visualized below.

Figure 1: Optimized workflow for deep ubiquitinome analysis, highlighting critical steps including bRPLC fractionation, diGly enrichment, and DIA mass spectrometry.

For mass spectrometric analysis, a data-independent acquisition (DIA) method was specifically optimized for diGly peptide characteristics:

• Customized window schemes: DIA window widths were adjusted based on empirical precursor distributions, increasing identified diGly peptides by 6% [8].
• Optimized parameters: A method with 46 precursor isolation windows and high MS2 resolution (30,000) improved identifications by 13% compared to standard proteome methods [8].
• Enhanced sensitivity: This DIA-based workflow identified approximately 35,000 diGly peptides in single measurements of proteasome inhibitor-treated cells—doubling the number achievable with data-dependent acquisition (DDA) methods [8].

Key Reagents and Research Solutions

Table 1: Essential research reagents for diGly proteomics workflows

Reagent/Category	Specific Examples	Function & Application Notes
diGly Antibodies	PTMScan Ubiquitin Remnant Motif (K-ε-GG) Kit (CST) [8] [2]	Immunoaffinity enrichment of diGly-modified peptides from complex digests
Chromatography Media	bRPLC C18 material (300 Å, 50 µM) [16]	High-pH fractionation to reduce sample complexity prior to enrichment
Protease Inhibitors	N-Ethylmaleimide (NEM) [2]	Deubiquitinase inhibition during lysis (note: some protocols omit due to unwanted modifications [16])
Cell Culture Reagents	SILAC DMEM (lysine/arginine-free) [2]	Metabolic labeling for quantitative ubiquitinome comparisons
Lysis Buffer Components	8M Urea, 150mM NaCl, 50mM Tris-HCl [2]	Effective protein extraction while maintaining ubiquitination status
Proteases	LysC, Trypsin (TPCK-treated) [2] [16]	Sequential digestion generating diGly remnants with defined C-termini

Quantitative Performance of the Optimized Workflow

Unprecedented Depth of Ubiquitinome Coverage

The implementation of the comprehensive bRPLC-DIA workflow resulted in remarkable quantitative improvements in diGly peptide identification, as summarized in the table below.

Table 2: Performance comparison of diGly proteomics methods

Methodological Approach	Number of diGly Sites Identified	Quantitative Precision (CV)	Sample Type
bRPLC-DIA (This study)	35,111 ± 682 (single measurement) [8]	45% of peptides <20% CV [8]	MG132-treated HEK293 cells
Conventional DDA	~17,500 (single measurement) [8]	Not specified; lower than DIA [8]	MG132-treated HEK293 cells
bRPLC with Advanced Fragmentation	>23,000 (single sample) [5] [16]	Not specified	HeLa cells (proteasome inhibited)
Direct DIA (no library)	26,780 ± 59 (single measurement) [8]	Not specified	MG132-treated HEK293 cells
Three-Fraction bRPLC	~10,000 (untreated cells) [16]	Not specified	HeLa cells (untreated)

The spectral libraries generated encompassed an unprecedented 89,650 diGly sites corresponding to 93,684 unique diGly peptides, with 43,338 detected in at least two libraries [8]. According to the PhosphositePlus database, 57% of identified diGly sites had not been previously reported, substantially expanding the known ubiquitinome [8].

Enhanced Quantitative Reproducibility

The DIA-based diGly workflow demonstrated exceptional reproducibility across biological and technical replicates:

• Low variability: Across three independent diGly peptide enrichments analyzed in duplicate, 77% of the approximately 36,000 distinct diGly peptides identified showed coefficients of variation (CVs) below 50% [8].
• Superior accuracy: DIA quantification significantly outperformed DDA in quantitative accuracy, with nearly half of all peptides demonstrating high precision (CV < 20%) [8].

This reproducibility is crucial for detecting subtle but biologically significant changes in ubiquitination across experimental conditions.

Applications in Biological Research

Case Study: Circadian Biology Regulation

Application of the optimized workflow to circadian biology revealed extensive ubiquitination regulation throughout the circadian cycle:

• Cycling ubiquitination sites: Hundreds of cycling ubiquitination sites were discovered, with dozens forming cycling ubiquitin clusters within individual membrane protein receptors and transporters [8].
• Non-degradative functions: These findings highlighted novel connections between metabolism and circadian regulation, suggesting ubiquitination roles beyond protein degradation in circadian biology [8] [31].

The following diagram illustrates the biological insights gained from applying the diGly proteomics workflow to circadian regulation studies:

Figure 2: Biological insights into circadian regulation enabled by comprehensive ubiquitinome profiling, revealing cycling ubiquitination sites and clusters in membrane proteins.

Case Study: Neurodegenerative Disease Mechanisms

The bRPLC-diGly workflow has also been successfully applied to investigate ubiquitination in disease contexts, particularly neurodegenerative disorders:

• Huntington's disease research: Analysis of the Q175 knock-in Huntington disease mouse model identified specific ubiquitination changes in mutant huntingtin, including increased K6 and K9 ubiquitination in insoluble fractions [32].
• Pathological insights: Besides huntingtin, proteins involved in membrane organization, mRNA processing, oxidative phosphorylation, and other pathways showed differential ubiquitination, suggesting novel mechanisms in Huntington's disease pathogenesis [32].

Case Study: TNF-α Signaling Pathway

When applied to TNF-α signaling, the optimized workflow comprehensively captured known ubiquitination sites while adding many novel ones [8]. This demonstrated the method's effectiveness in mapping ubiquitination events in well-characterized signaling pathways, potentially revealing new regulatory mechanisms in inflammatory and immune responses.

Step-by-Step Protocol for diGly Peptide Enrichment

Sample Preparation and Lysis

• Cell Culture and Treatment:

  • Culture cells in appropriate medium (e.g., DMEM with 10% FBS). For quantitative experiments, use SILAC media with heavy lysine (K8) and arginine (R10) for at least six doublings [2].
  • Treat cells with proteasome inhibitor (e.g., 10µM MG132 for 4 hours or 10µM bortezomib for 8 hours) to enhance ubiquitinated protein detection [8] [16].

• Lysis and Protein Extraction:

  • Lysate cells in ice-cold urea buffer (8M urea, 150mM NaCl, 50mM Tris-HCl, pH 8.0) supplemented with protease inhibitors [2].
  • Include 5mM N-ethylmaleimide (NEM) to inhibit deubiquitinases (optional; some protocols omit due to potential unwanted modifications) [2] [16].
  • Boil lysates at 95°C for 5 minutes, then sonicate for 10 minutes at 4°C [16].

• Protein Digestion:

  • Reduce proteins with 5mM DTT (30 minutes, 50°C) and alkylate with 10mM iodoacetamide (15 minutes, dark) [2] [16].
  • Digest first with LysC (1:200 enzyme-to-substrate ratio, 4 hours) followed by trypsin (1:50 ratio, overnight, 30°C) [2].
  • Acidify with TFA to 0.5% final concentration and centrifuge to remove precipitates [16].

bRPLC Fractionation and diGly Enrichment

• Basic pH Reversed-Phase Fractionation:

  • Load peptides onto a C18 column (300Å, 50µM) with bed size adjusted to protein amount (1:50 ratio) [16].
  • Wash with 10 column volumes of 0.1% TFA followed by 10 volumes of H₂O [16].
  • Elute peptides with 10mM ammonium formate (pH 10) containing stepwise increasing ACN concentrations (7%, 13.5%, 50%) [8] [16].
  • Lyophilize fractions completely before enrichment.

• diGly Peptide Immunoprecipitation:

  • Use ubiquitin remnant motif (K-ε-GG) antibodies conjugated to protein A agarose beads [16].
  • Wash beads twice with PBS and split according to manufacturer's batch definitions [16].
  • Resuspend lyophilized peptides in immunoaffinity purification buffer (IAP) and incubate with antibody beads for 2 hours at 4°C [2].
  • Wash beads extensively with IAP buffer followed by water to remove non-specifically bound peptides [5].

• Peptide Elution and Cleanup:

  • Elute diGly peptides with 0.2% TFA [2].
  • Desalt using StageTips or C18 cartridges [2].
  • Lyophilize and reconstitute in MS loading buffer for analysis.

Mass Spectrometry Analysis

• Liquid Chromatography:

  • Separate peptides using acidic pH nanoflow LC with C18 column [8].

• Data Acquisition:

  • Utilize Orbitrap mass spectrometer with optimized DIA method [8].
  • Employ 46 variable windows covering 400-1000 m/z range [8].
  • Use high MS2 resolution (30,000) for improved identification [8].

• Data Analysis:

  • Process DIA data using spectral libraries generated from combined bRPLC fractions [8].
  • Search data against appropriate protein databases using software like Spectronaut or Skyline [8].

The integration of basic pH reversed-phase chromatography with diGly peptide enrichment and advanced DIA mass spectrometry represents a transformative advancement in ubiquitinome research. This optimized workflow enables the comprehensive identification of over 90,000 diGly sites and the quantitative analysis of more than 35,000 distinct diGly peptides in single measurements—far surpassing previous methodological capabilities.

The application of this approach across diverse biological contexts, from circadian regulation to disease mechanisms, has unveiled unprecedented insights into the scope and dynamics of protein ubiquitination. The detailed protocol provided herein empowers researchers to implement this cutting-edge methodology in their own investigations, potentially accelerating discoveries in cell signaling, disease pathogenesis, and therapeutic development.

In depth proteomics research, the analysis of post-translational modifications such as lysine ubiquitination—commonly enriched via diGly remnant immunoaffinity purification—demands sophisticated fractionation strategies to achieve comprehensive coverage. Basic pH reversed-phase liquid chromatography (bRPLC) serves as a powerful orthogonal separation technique to low pH reverse-phase chromatography used in LC-MS/MS, significantly reducing sample complexity before mass spectrometric analysis. The configuration of bRPLC, whether operated in online or offline mode relative to the diGly enrichment and MS injection workflow, profoundly impacts experimental outcomes in terms of resolution, sensitivity, and practicality. This application note provides detailed protocols and comparative analysis to guide researchers in selecting and implementing the optimal bRPLC configuration for their diGly peptide research, framed within the broader context of basic pH reversed-phase chromatography for proteomic fractionation.

Theoretical Foundations of bRPLC Separation

Fundamental Principles of Basic pH Reversed-Phase Chromatography

Basic pH reversed-phase chromatography operates on the principle of hydrophobic interactions between peptide molecules and the non-polar stationary phase under alkaline mobile phase conditions (typically pH 8-10). Unlike traditional reversed-phase chromatography operated at acidic pH, bRPLC utilizes high pH mobile phases containing additives such as 0.1% triethylamine or 20 mM ammonium bicarbonate (pH 8.5) to promote alternative separation selectivity based on peptide hydrophobicity [33] [34]. The mechanism involves the distribution of analytes between a polar mobile phase and nonpolar stationary phase, where retention increases with peptide hydrophobicity but follows a different elution profile compared to acidic pH separations due to altered ionization states of acidic and basic residues [35]. This orthogonal separation mechanism makes bRPLC particularly valuable for proteomic applications where maximum peak capacity is required for complex peptide mixtures.

The enhanced separation efficiency of bRPLC stems from several factors: First, the high pH environment suppresses the ionization of acidic residues (aspartic and glutamic acid), increasing peptide hydrophobicity and retention compared to low pH conditions. Second, the silica-based stationary phases commonly used in bRPLC (typically C18-modified with enhanced pH stability) exhibit different selectivity profiles under basic conditions. Third, the compatibility of high pH mobile phases with mass spectrometry detection—when properly combined with online neutralization or used in offline workflows—enables effective two-dimensional separation strategies [33]. This orthogonal separation approach has been demonstrated to increase protein identification rates by ≥50% compared to unfractionated samples in proteomic studies [34].

Orthogonality in Multi-Dimensional Separations for diGly Proteomics

The effectiveness of any multi-dimensional separation system depends on the orthogonality between dimensions—the degree to which different separation mechanisms contribute independently to overall peak capacity. For diGly peptide analysis, the combination of bRPLC with subsequent low pH nanoLC-MS/MS provides exceptional orthogonality because the separation mechanisms operate on fundamentally different principles [33]. While low pH reverse-phase chromatography separates peptides primarily based on hydrophobicity with contributions from ion exchange interactions due to acidic modifiers, bRPLC at high pH alters the ionization state of acidic residues and provides a distinct selectivity profile based on hydrophobicity without ionic contributions from the mobile phase.

This orthogonality is quantitatively demonstrated in the improved identification rates for post-translationally modified peptides. Research shows that bRPLC fractionation prior to LC-MS analysis increases the number of quantifiable peptides/proteins for multiplexed samples, with particularly notable improvements for modified peptides such as those containing diGly remnants [34]. The orthogonality between high pH and low pH reverse-phase separations exceeds that of other common two-dimensional chromatography combinations such as strong cation exchange-reverse phase (SCX-RP), while avoiding the need for additional desalting steps required between SCX and RP dimensions [33] [34].

Comparative Analysis: Online vs. Offline bRPLC Configuration

The integration of bRPLC with diGly immunoaffinity enrichment and MS injection can be implemented in either online or offline configurations, each with distinct technical considerations and performance characteristics. The following comparative analysis examines both approaches across multiple critical parameters.

Table 1: Configuration Comparison of Online vs. Offline bRPLC-diGly-MS Integration

Parameter	Online bRPLC Configuration	Offline bRPLC Configuration
System Complexity	High; requires precise valve switching, mobile phase compatibility management, and real-time mixing apparatus	Moderate; utilizes standard HPLC equipment with fraction collection capabilities
Automation Potential	Full automation from sample injection to MS analysis	Partial automation; requires manual fraction handling and reconstitution
Risk of Sample Loss	Lower; closed system minimizes handling and transfer losses	Higher potential for adsorption and transfer losses during fraction handling
Analysis Time	Generally faster; continuous operation without intermediate steps	Longer overall process due to fraction collection, drying, and reconstitution
Mobile Phase Compatibility	Challenging; requires careful management of pH transition between dimensions	Flexible; allows complete solvent removal and compatibility optimization between steps
Fraction Resolution	Limited by valve loop capacity and transfer efficiency	High resolution; customizable fraction collection intervals based on UV profile
Method Development	Complex; requires optimization of multiple coupled parameters	Simplified; each dimension can be optimized independently
Scalability	Limited by system complexity and potential for carryover	Highly scalable; parallel processing of multiple fractions possible
Reproducibility	High run-to-run consistency once optimized	Potential for variability in fraction handling and reconstitution

Technical Implementation Considerations

Mobile Phase Compatibility Management represents perhaps the most significant technical challenge in online bRPLC configuration. The high pH mobile phases used in bRPLC (typically pH 8-10) are incompatible with both the immunoaffinity enrichment steps (which generally require near-physiological pH conditions) and with subsequent low pH LC-MS analysis (which employs acidic mobile phases for optimal electrospray ionization) [33]. In online systems, this necessitates sophisticated mixing tees or neutralization devices that can adjust pH in real-time before MS injection, potentially introducing band broadening or dilution effects. Offline configurations circumvent this limitation by allowing complete evaporation of the high pH mobile phase between separation dimensions, followed by reconstitution in solvents compatible with subsequent analytical steps [34].

System Pressure Considerations differ markedly between configurations. Online bRPLC operation typically employs narrower bore columns (100-150 μm inner diameter) and lower flow rates (1.0-1.2 μL/min) to maintain compatibility with nanoLC-MS systems, resulting in higher operating pressures and increased susceptibility to clogging from precipitated salts or particulates [33]. Offline bRPLC can utilize wider bore columns (2.1-4.6 mm inner diameter) with higher flow rates (0.1-1.0 mL/min), offering more stable operation and easier troubleshooting. The difference in column geometry also affects loading capacity, with offline systems typically accommodating 0.1-1 mg of peptide material compared to ng-μg levels for online systems [33].

Experimental Protocols

Offline bRPLC-diGly-MS Workflow Protocol

Materials and Reagents:

• Pierce High pH Reversed-Phase Peptide Fractionation Kit (or equivalent bRPLC columns) [34]
• Ammonium bicarbonate (20 mM, pH 8.5) or triethylamine (0.1%) in water [33]
• Acetonitrile (HPLC grade)
• Water (LC-MS grade)
• Formic acid (0.1% in water for reconstitution)
• diGly antibody-conjugated beads (commercial or custom)
• Binding and wash buffers compatible with diGly immunoaffinity enrichment

Step-by-Step Procedure:

• Sample Preparation: Digest protein extract using trypsin or appropriate protease. Desalt peptides using C18 solid-phase extraction if necessary.

• diGly Immunoaffinity Enrichment:

  • Incubate peptide digest with diGly antibody-conjugated beads in binding buffer for 2 hours at 4°C with gentle agitation.
  • Wash beads 3-5 times with appropriate wash buffer to remove non-specifically bound peptides.
  • Elute diGly-modified peptides using 0.1-0.5% trifluoroacetic acid or low pH elution buffer.
  • Lyophilize eluted peptides completely and reconstitute in 100 μL of 20 mM ammonium bicarbonate (pH 8.5).

• bRPLC Fractionation:

  • Condition bRPLC spin column with 100% acetonitrile, followed by equilibration with 20 mM ammonium bicarbonate (pH 8.5).
  • Load diGly-enriched peptide sample (10-100 μg) onto conditioned column [34].
  • Perform stepwise or gradient elution using increasing concentrations of acetonitrile (5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 50%) in 20 mM ammonium bicarbonate (pH 8.5).
  • Collect each fraction in separate low-binding tubes.
  • Completely dry fractions using vacuum centrifugation.

• LC-MS/MS Analysis:

  • Reconstitute each fraction in 0.1% formic acid for LC-MS analysis.
  • Perform low pH nanoLC-MS/MS using C18 reverse-phase columns with standard acidic gradients.

• Data Processing:

  • Search MS/MS data against appropriate protein database with diGly (K-ε-GG) as variable modification.
  • Combine identification results from all fractions for comprehensive diGly proteome analysis.

Table 2: Typical bRPLC Fractionation Scheme for diGly-Enriched Peptides

Fraction Number	ACN Concentration (%)	Expected Peptide Characteristics	Collection Interval (min)
1	5	Highly hydrophilic peptides	0-5
2	7.5	Moderately hydrophilic peptides	5-10
3	10	Transition zone peptides	10-15
4	12.5	Early eluting hydrophobic peptides	15-20
5	15	Medium hydrophobic peptides	20-25
6	17.5	Late eluting hydrophobic peptides	25-30
7	20	Highly hydrophobic peptides	30-35
8	25	Very hydrophobic peptides	35-40
9	30	Extremely hydrophobic peptides	40-45
10	50	Membrane protein peptides	45-50

Online bRPLC-diGly-MS Workflow Protocol

Materials and Reagents:

• Two-dimensional nanoLC system with switching valves
• bRPLC column (e.g., XBridge BEH C18, 300 μm × 50 mm, 3.5 μm)
• Analytical nanoLC column (e.g., BEH C18, 75 μm × 250 mm, 1.7 μm)
• Mobile phase A: 20 mM ammonium bicarbonate, pH 8.5
• Mobile phase B: acetonitrile with 20 mM ammonium bicarbonate, pH 8.5
• Mobile phase C: 0.1% formic acid in water
• Mobile phase D: 0.1% formic acid in acetonitrile
• diGly-enriched peptide sample

Step-by-Step Procedure:

• System Configuration:

  • Configure the 2D-nanoLC system with two switching valves allowing independent operation of first and second dimensions.
  • Install bRPLC column in first dimension and analytical nanoLC column in second dimension.
  • Ensure proper fluidic connections with minimal dead volume.

• Sample Loading and First Dimension Separation:

  • Load diGly-enriched peptide sample onto bRPLC column using autosampler.
  • Apply shallow gradient from 5% to 30% mobile phase B over 60 minutes at flow rate of 2 μL/min.
  • Transfer eluting peptides sequentially to trapping column using multiple fraction cuts (typically 12-24 fractions).

• Second Dimension Separation and MS Analysis:

  • For each trapped fraction, switch valve to position trapping column in line with analytical nanoLC column.
  • Perform rapid gradient separation (15-30 minutes) using standard acidic reverse-phase conditions (increasing mobile phase D).
  • Elute peptides directly into mass spectrometer for data-dependent MS/MS analysis.

• System Regeneration:

  • Re-equilibrate bRPLC column with starting conditions between fraction transfers.
  • Ensure complete flushing of trapping column with starting solvents before next fraction transfer.

Data Analysis and Interpretation

Quantitative Assessment of bRPLC Performance

The effectiveness of bRPLC fractionation for diGly peptide analysis can be evaluated through multiple quantitative metrics. Typical performance benchmarks include a 30-50% increase in diGly peptide identifications compared to unfractionated samples, with similar improvements in quantitative precision for multiplexed experiments [34]. The orthogonality between separation dimensions can be visualized using 2D-peptide distribution plots, where ideal separation shows even distribution of peptides across the separation space rather than diagonal clustering.

Table 3: Expected Performance Metrics for bRPLC-diGly Workflows

Performance Metric	Offline bRPLC Configuration	Online bRPLC Configuration	Unfractionated Control
Total diGly Peptide Identifications	8,000-12,000	6,000-9,000	4,000-6,000
Total diGly Protein Identifications	2,500-4,000	2,000-3,000	1,200-2,000
Sequence Coverage	35-50%	30-45%	15-25%
Quantitative Precision (CV)	<15%	<20%	20-30%
Sample Processing Time	24-36 hours	12-18 hours	2-4 hours
Technical Reproducibility	>85% peptide overlap between replicates	>90% peptide overlap between replicates	>95% peptide overlap between replicates

Troubleshooting Common Issues

Poor Fractionation Resolution in bRPLC can result from several factors: Column overloading (exceeding 100 μg peptide load for standard columns), suboptimal pH control (deviation from pH 8.5±0.2), or excessive gradient speed. Remedy by reducing sample load, verifying mobile phase pH, and implementing shallower gradients (0.5% ACN/min instead of 1% ACN/min) [34].

Low diGly Peptide Recovery after bRPLC may indicate adsorption issues or incompatible solvent conditions. Utilize low-binding tubes throughout, add small amounts of detergent (0.0001% n-dodecyl-β-D-maltoside) to reconstitution solvents, and ensure complete drying of bRPLC fractions before reconstitution in MS-compatible solvents [33].

Incomplete Orthogonality between bRPLC and subsequent low pH LC-MS manifests as peptide clustering in specific fractions rather than even distribution. This can be addressed by optimizing the bRPLC gradient shape, testing alternative high pH buffers (ammonium bicarbonate vs. triethylamine), or increasing the number of fractions collected during bRPLC separation [33] [34].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Essential Research Reagents for bRPLC-diGly Workflows

Item	Function	Example Products	Usage Notes
High pH Stable RP Columns	Peptide fractionation under basic conditions	Pierce High pH RP Spin Columns, XBridge BEH C18	Ensure pH stability up to pH 11 for extended column lifetime
diGly Antibody Beads	Immunoaffinity enrichment of ubiquitinated peptides	PTMScan Ubiquitin Remnant Motif (K-ε-GG) Kit	Critical for specific isolation of diGly-modified peptides from complex digests
pH-Stable Mobile Phase Additives	Maintaining optimal separation conditions	Ammonium bicarbonate, triethylamine	Prepare fresh solutions to prevent pH drift due to CO₂ absorption
Peptide Desalting Columns	Sample cleanup before bRPLC	Pierce Peptide Desalting Spin Columns	Essential for removing interfering salts and detergents before fractionation
Low-Binding Collection Tubes	Minimizing peptide adsorption during processing	Protein LoBind Tubes	Significantly improve recovery of low-abundance diGly peptides
LC-MS Grade Solvents	Maintaining system performance and sensitivity	Water, acetonitrile, methanol	Impurities in solvents cause ion suppression and background interference

Workflow Visualization

Diagram 1: Comprehensive diGly Proteomics Workflow Integrating bRPLC Fractionation

Diagram 2: Configuration Comparison Between Online and Offline bRPLC Setups

Solving Common Challenges in bRPLC for diGly Peptides: Peak Shape, Recovery, and MS Signal

In the field of proteomics, particularly in the analysis of post-translational modifications such as ubiquitination, basic pH reversed-phase chromatography (bRPLC) is a critical fractionation technique. The separation of diglycine (diGly)-modified peptides, which serve as a signature for ubiquitination sites, is notoriously challenging due to their physicochemical properties. These analytes are highly susceptible to metal surface interactions with traditional stainless steel high-performance liquid chromatography (HPLC) hardware. These unwanted interactions manifest analytically as peak tailing and poor analyte recovery, compromising sensitivity, quantitative accuracy, and reproducibility. This application note details the sources of these metal interactions and presents inert hardware solutions, providing validated data and detailed protocols to empower researchers in drug development and related fields to achieve superior chromatographic results.

The Problem: Metal Interference in Chromatographic Analysis

Mechanisms of Metal-Analyte Interaction

Metal surfaces in conventional HPLC systems (e.g., stainless steel column hardware, frits, and tubing) can actively interfere with the analysis of metal-sensitive compounds. The primary mechanisms include:

• Ionic Interactions: Positively charged metal surfaces on the column hardware or frits can interact with electron-rich functional groups on analytes, leading to irreversible adsorption or delayed elution [36] [37].
• Coordination and Chelation: Analytes with specific functional groups, such as carboxylic acids, phosphates, and hydroxyl groups, can chelate metal ions (e.g., Fe²⁺, Ti³⁺) that have leached from system components, resulting in severe peak tailing and loss of recovery [38] [39].
• Catalysis of Oxidation: Metal surfaces can catalyze the oxidation of susceptible compounds, further contributing to analyte loss [37].

Analytes at High Risk

The following classes of compounds, common in (bio)pharmaceutical and proteomic research, are particularly prone to metal-mediated issues [36] [37]:

• Phosphorylated Compounds: Phosphopeptides, phosphorylated nucleotides (AMP, ADP, ATP), and phospholipids.
• Acidic Metabolites: Molecules containing multiple carboxylate groups, such as those in the tricarboxylic acid (TCA) cycle.
• Oligonucleotides: The electron-rich phosphate backbone readily adsorbs to metal surfaces.
• diGly-Modified Peptides: The backbone and the modified lysine residue can interact with metal ions.
• Antibodies and Proteins: Especially under native mass spectrometry conditions.
• Small Chelating Molecules: Antibiotics like ciprofloxacin and various metabolites.

The following diagram illustrates how metal interactions at different points in the HPLC system lead to peak tailing and poor recovery.

Quantitative Comparison of Hardware Performance

The impact of column hardware material on chromatographic performance is profound and quantifiable. The following tables summarize key experimental data demonstrating the superiority of inert hardware.

Table 1: Impact of Inert Hardware on Relative Signal Intensity and Peak Tailing [36]

Analyte Class	Specific Analytes	Stainless Steel (Relative Height %)	Inert Hardware (Relative Height %)	Improvement Factor	Tailing Factor (SS)	Tailing Factor (Inert)
Synthetic Peptides	Peptide b (phospho)	Undetectable	~150%	N/A	N/A	N/A
	Peptide c (phospho)	~50%	~150%	3x	1.9	1.4
	Peptide a	~150%	~150%	~1x	1.2	1.0
Phosphorylated Nucleotides	AMP	~50%	~150%	~3x	2.6	1.3
	ADP	~40%	~150%	~3.75x	4.8	1.7
	ATP	~30%	~150%	~5x	N/A	N/A
Acidic Metabolites	Glutamine	~40%	~150%	~3.75x	1.8	1.2
	Glutamate	~70%	~150%	~2x	1.4	1.3
	Malate	~30%	~150%	~5x	N/A	N/A

Table 2: Performance of DIA vs. DDA for diGly Peptide Analysis [3]

Metric	Data-Dependent Acquisition (DDA)	Data-Independent Acquisition (DIA)
Distinct diGly Peptides (single run)	~20,000	~35,000
Quantitative Reproducibility (CV < 20%)	15% of peptides	45% of peptides
Total Peptides (6 runs)	~24,000	~48,000
Key Advantage	-	Superior sensitivity, completeness, and quantitative accuracy

Solutions: Inert Hardware and Optimized Protocols

Types of Bioinert HPLC Hardware

Several technologies are available to mitigate metal interactions, each with distinct advantages and limitations [36] [37] [38].

• PEEK and PEEK-Lined Stainless Steel: Provides a full polymer flow path but is incompatible with many organic solvents and lacks the pressure stability of steel.
• Titanium Hardware: Offers high mechanical strength but is susceptible to corrosion by pure organic solvents, leading to Ti³⁺ leaching which can contaminate the stationary phase [38].
• Coated Stainless Steel (Ultra Inert): Features an advanced, inert coating on stainless steel hardware. This option blocks metal interactions while maintaining the mechanical strength, chemical stability, and high-pressure compatibility of traditional steel columns [36]. This is often the optimal choice for high-sensitivity bRPLC applications.

Optimized Protocol: Deep Ubiquitinome Analysis Using bRPLC and Inert Hardware

The following detailed protocol, adapted from recent literature, is specifically designed for the fractionation of diGly peptides prior to mass spectrometric analysis, incorporating inert strategies to maximize recovery [3] [5].

Protocol: Micro-Scale Basic Reversed-Phase Fractionation of diGly Peptides

Objective: To efficiently fractionate complex diGly peptide mixtures from small samples (5-20 µg) for deep ubiquitinome coverage while minimizing metal-mediated losses.

Research Reagent Solutions:

Item	Function	Specific Example/Note
Inert C18 Microcolumn	Core separation media; inertness prevents peptide adsorption.	Jupiter C18 material (5 µm), packed in C18 StageTip [14].
Ammonium Bicarbonate Buffer	Creates basic pH mobile phase for bRPLC separation.	100 mM, pH 8.0 [14].
Acetonitrile (ACN)	Organic modifier for gradient elution.	HPLC or MS-grade.
Formic Acid (FA)	Ion-pairing agent for MS-compatible mobile phases.	Added at 0.1% in water and ACN [3].
Anti-diGly Antibody	Immunoaffinity enrichment of ubiquitinated peptides.	Essential for ubiquitinome depth [3].
Triethylammonium Bicarbonate (TEAB)	Buffer for iTRAQ labeling.	500 mM, pH 8.5 [14].

Step-by-Step Procedure:

• Sample Preparation and Digestion:

  • Lyse cells or tissue in a denaturing buffer (e.g., 8 M urea, 100 mM NH₄HCO₃, pH 8.0) supplemented with protease and phosphatase inhibitors.
  • Reduce proteins with 10 mM dithiothreitol (37°C, 30 min) and alkylate with 20 mM iodoacetamide (room temperature, 20 min in the dark).
  • Dilute the urea concentration to ~1 M and digest with trypsin (enzyme-to-substrate ratio 1:50) at 37°C for 16 hours.

• diGly Peptide Enrichment:

  • Use anti-diGly remnant motif antibodies for immunoaffinity enrichment.
  • Critical Step: Prior to enrichment, perform a fast, offline basic reversed-phase pre-fractionation into a limited number of fractions (e.g., 3-8) to reduce sample complexity and separate the highly abundant K48-linked ubiquitin chain-derived diGly peptide, which can compete for antibody binding sites [3] [5].
  • For enrichment from 1 mg of peptide material, use 31.25 µg of anti-diGly antibody. Perform wash steps efficiently, using a filter plug to retain antibody beads and minimize non-specific binding [3] [5].

• Micro-Scale bRPLC Fractionation (StageTip):

  • Prepare a microcolumn by packing 2 mg of Jupiter C18 resin (5 µm) into a commercially available C18 StageTip [14].
  • Condition the column with 100 µL of 100% acetonitrile, followed by 100 µL of equilibration buffer (100 mM NH₄HCO₃, pH 8.0). Use benchtop centrifugation (3,000 × g for 3 min) for all elution steps.
  • Load the enriched diGly peptide mixture onto the conditioned column.
  • Elute peptides sequentially using 100 µL of the following elution buffers in 100 mM NH₄HCO₃ (pH 8.0): 5%, 10%, 15%, 20%, 25%, 30%, and 90% acetonitrile.
  • Collect each fraction separately and evaporate to dryness in a vacuum concentrator.

• LC-MS/MS Analysis:

  • Reconstitute fractions in a MS-compatible solvent (e.g., 3% ACN, 0.1% formic acid).
  • Analyze using a nano-flow LC system coupled to a high-resolution mass spectrometer (e.g., Orbitrap).
  • Chromatography: Use an inert reversed-phase column (e.g., Acclaim PepMap C18, 75 µm id × 500 mm). Employ a gradient from 3% to 32% mobile phase B (0.1% formic acid in ACN) over 75-140 min at a flow rate of 450 nL/min [14] [3].
  • Mass Spectrometry: For deepest coverage, utilize Data-Independent Acquisition (DIA). A method with 46 precursor isolation windows and MS2 resolution of 30,000 is recommended for optimal diGly peptide identification and quantification [3].

The following workflow diagram provides a visual summary of this optimized protocol for diGly peptide analysis.

The challenges of peak tailing and poor recovery in the analysis of metal-sensitive species like diGly peptides are primarily consequences of analyte interactions with metal surfaces in the chromatographic flow path. These issues are not merely inconveniences; they directly impede the sensitivity, accuracy, and depth of proteomic and drug development research. As demonstrated by the quantitative data, transitioning to inert HPLC hardware represents a fundamental solution, providing significant gains in signal intensity, peak shape, and quantitative reproducibility. When combined with optimized protocols—including basic reversed-phase pre-fractionation and modern DIA mass spectrometry—researchers can achieve unprecedented coverage of the ubiquitinome. Adopting these inert solutions is therefore critical for advancing systems-level biological investigations and for ensuring robust, reliable analytical methods in pharmaceutical development.

Managing High-Abundance Ubiquitin Chain Peptides (e.g., K48-peptide) to Prevent Ion Suppression

In quantitative ubiquitinomics, the accurate measurement of endogenous ubiquitin chain linkages is paramount for understanding their distinct cellular functions. However, the widespread adoption of diGLY remnant enrichment techniques coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) faces a significant analytical challenge: ion suppression. This phenomenon occurs when matrix components, including highly abundant ubiquitin-derived peptides, interfere with the ionization efficiency of co-eluting target analytes in the mass spectrometer source [40] [41]. The consequence is a reduction in signal intensity, compromised detection capability, and ultimately, inaccurate quantification [41] [42].

Among all ubiquitin chain types, the K48-linked polyubiquitin chain is notably problematic. Studies have revealed that K48 linkages are exceptionally abundant in vivo, constituting approximately 29.1% ± 1.9% of the total conjugated ubiquitin pool [43]. When analyzing complex peptide mixtures derived from cellular lysates, the corresponding K48-GG signature peptide can reach concentrations that dominate the MS signal. During electrospray ionization, this abundance leads to competition for charge and space on the droplet surface, effectively suppressing the ionization of less abundant but biologically critical peptides, such as those from unconventional linkages (K6, K11, K27, K29, K33) or low-abundance monoubiquitination sites [43] [40]. This review details strategic methods to manage high-abundance ubiquitin chain peptides, with a specific focus on techniques compatible with basic pH reversed-phase chromatography, to ensure comprehensive and accurate ubiquitinome analysis.

Quantitative Profiling of Ubiquitin Chain Linkages

A foundational understanding of the relative abundance of different ubiquitin linkages is crucial for appreciating the scale of the ion suppression challenge. The following table summarizes the measured abundance of each polyubiquitin linkage type in yeast, as determined by absolute quantification using mass spectrometry with isotope-labeled internal standards [43].

Table 1: Absolute Abundance of Polyubiquitin Linkages in Vivo

Ubiquitin Linkage	Percent Abundance (%)	Role in Proteasomal Degradation
K48	29.1 ± 1.9	Primary canonical degradation signal
K11	28.0 ± 1.4	Supports ERAD and proteasomal degradation
K63	16.3 ± 0.2	Predominantly non-proteolytic roles
K6	10.9 ± 1.9	Targets proteins for degradation
K27	9.0 ± 0.1	May target proteins for degradation
K33	3.5 ± 0.1	May target proteins for degradation
K29	3.2 ± 0.1	May participate in Ub-fusion degradation

This quantitative profile reveals that non-K48 linkages are far more abundant than previously recognized, collectively forming a major component of the conjugated ubiquitin pool [43]. Their accurate quantification is essential, as evidence suggests that all non-K63 linkages can target substrates for proteasomal degradation [43]. The high abundance of the K48-linked peptide, however, poses a substantial risk of ion suppression, potentially masking the detection and precise quantification of these other biologically active chains.

Mechanisms and Evaluation of Ion Suppression

Fundamental Causes of Ion Suppression

Ion suppression primarily occurs in the ion source of the mass spectrometer and is a manifestation of matrix effects. In the context of diGLY proteomics, key causes include:

• Competition for Charge (ESI): In electrospray ionization (ESI), the process has a limited capacity for ion current. When highly abundant peptides like the K48-GG peptide are present at high concentrations, they monopolize the available charge, leaving less abundant co-eluting peptides unable to ionize efficiently [40] [41].
• Altered Droplet Properties: High concentrations of interfering compounds can increase the viscosity and surface tension of ESI droplets, impairing solvent evaporation and the subsequent release of gas-phase analyte ions [40] [41].
• Co-elution with Matrix Components: The core of the problem is chromatographic. If the K48 peptide is not sufficiently separated from other diGLY peptides in the LC dimension, it will cause localized ion suppression in its specific retention time window [40] [41].

Detecting and Evaluating Ion Suppression

It is critical to validate the presence and extent of ion suppression in any developed method. Two common experimental protocols are:

• Post-extraction Addition Method: Compare the MS response of a target analyte spiked into a blank, enriched sample matrix to its response in a pure solvent. A significantly lower signal in the matrix indicates ion suppression [40] [41].
• Continuous Post-column Infusion: A solution containing standard diGLY peptides is infused into the MS via a T-fitting post-column while a blank, enriched sample is injected into the LC system. A drop in the baseline signal in the resulting chromatogram directly visualizes the retention time windows affected by ion suppression [40].

Strategic Workflow for Managing Abundant Peptides

A multi-pronged approach is required to mitigate ion suppression caused by high-abundance ubiquitin chain peptides. The most effective strategies involve a combination of pre-fractionation, optimized chromatography, and advanced MS acquisition techniques.

Diagram 1: Strategic workflow for managing abundant peptides.

Basic pH Reversed-Phase Peptide Fractionation

A powerful strategy to prevent ion suppression is to separate the highly abundant K48 peptides from the rest of the diGLY peptide population before the final LC-MS/MS analysis. This is achieved through basic pH reversed-phase (bRP) fractionation [3].

• Principle: bRP chromatography separates peptides based on hydrophobicity at a high pH (typically ~pH 10). Under these conditions, the ionization of acidic and basic groups is altered, leading to a different separation selectivity compared to acidic pH LC-MS gradients.
• Application: A complex diGLY-enriched peptide sample is separated by bRP HPLC and collected into multiple fractions. Due to its unique sequence and hydrophobicity, the K48-GG peptide elutes in specific, predictable fractions.
• Protocol:
  • Sample Preparation: Digest protein lysates to peptides. It is critical to use a digestion buffer containing 8M Urea, 50mM Tris-HCl (pH 8), and protease inhibitors. Reduce disulfide bonds with DTT and alkylate with iodoacetamide before diluting the urea concentration and digesting with LysC and trypsin [2].
  • bRP Chromatography: Reconstitute the diGLY-enriched peptides in a basic mobile phase (e.g., 10mM Ammonium Bicarbonate, pH ~10). Use a C18 column and a gradient from 0% to 60% acetonitrile in the basic aqueous buffer. Collect 48-96 fractions.
  • Fraction Pooling: Identify and pool the fractions that are highly enriched for the K48-GG peptide (e.g., via pilot MS analysis). The remaining K48-depleted fractions can be pooled separately or in a structured (e.g., concatenated) manner. This process effectively reduces the dynamic range of the sample by isolating the most abundant suppressor [3].

Advanced Mass Spectrometry Acquisition Methods

To further combat the sensitivity issues caused by low-abundance peptides in a complex background, moving beyond traditional Data-Dependent Acquisition (DDA) is advisable.

• Data-Independent Acquisition (DIA): DIA, such as in the method developed by [3], fragments all ions within predefined m/z windows without regard to precursor intensity. This eliminates the stochasticity of DDA and increases the detection of low-abundance peptides. When combined with comprehensive spectral libraries (>90,000 diGLY peptides), DIA can identify over 35,000 distinct diGLY sites in a single measurement, doubling the coverage of DDA while significantly improving quantitative accuracy [3].
• Parallel Reaction Monitoring (PRM): For targeted quantification of specific ubiquitin linkages, PRM offers high sensitivity. This high-resolution, targeted MS method can quantify down to 100 attomole amounts of all possible ubiquitin chains in complex cell extracts, making it ideal for validating the levels of unconventional chains like K29-linkages [44].

Optimized diGLY Enrichment and Chromatography

• Anti-diGLY Antibody Enrichment: The core enrichment step should be optimized. Use the ubiquitin remnant motif (K-ε-GG) antibody under recommended conditions (e.g., 1 mg peptide input, 31.25 µg antibody) to ensure efficient capture without overloading [2] [3].
• Acidic pH LC-MS/MS Optimization: For the final analytical separation, optimize the chromatographic conditions to maximize resolution.
  • Mobile Phase pH: The use of volatile buffers like ammonium formate is standard. While adjusting pH within the stable range of the column (typically pH 3-7) can subtly alter the retention of ionizable diGLY peptides, its power for drastically shifting selectivity is more limited for these peptides compared to simpler small molecules [45].
  • Key Parameters: Focus on using long, shallow gradients and columns with high peak capacity to physically separate as many diGLY peptides as possible from the remaining K48 peptides and other matrix components.

The Scientist's Toolkit: Essential Reagents and Materials

Table 2: Key Research Reagents and Materials for diGLY Proteomics

Item	Function/Application	Example/Specification
Anti-diGLY (K-ε-GG) Antibody	Immunoaffinity enrichment of ubiquitinated peptides from complex digests.	PTMScan Ubiquitin Remnant Motif Kit (CST) [2] [3]
Stable Isotope-Labeled Ubiquitin Peptides	Internal standards for absolute quantification of ubiquitin chain linkages.	Chemically synthesized, heavy isotope-labeled GG-tagged peptides [43]
Basic pH Reversed-Phase Column	High-resolution fractionation of peptides to reduce dynamic range.	C18 column, stable at high pH (e.g., Zorbax 300Extend-C18) [3]
Protease Inhibitors	Prevent protein degradation and deubiquitination during cell lysis.	Complete Protease Inhibitor Cocktail (e.g., Roche) including N-Ethylmaleimide (NEM) to inhibit DUBs [2]
High-Purity Trypsin/LysC	Protein digestion to generate diGLY-modified peptides for MS analysis.	Sequencing grade, modified trypsin (e.g., Promega) [2]
Immunodepletion Kits	Optional removal of highly abundant plasma proteins prior to ubiquitinome analysis.	ProteoPrep20 (Sigma-Aldrich) for depleting top 20 plasma proteins [46] [47]

Concluding Protocol: A Consolidated Workflow

This protocol integrates the above strategies into a cohesive workflow for the sensitive analysis of the ubiquitinome while managing the K48 peptide.

Diagram 2: Consolidated workflow for ubiquitinome analysis.

• Sample Preparation and Digestion:

  • Lyse cells or tissues in a denaturing lysis buffer (8M Urea, 50mM Tris-HCl, pH 8, 150mM NaCl) supplemented with 5mM N-Ethylmaleimide (NEM) and protease inhibitors [2].
  • Reduce proteins with 5mM DTT (30 min, 25°C), alkylate with 15mM iodoacetamide (30 min, 25°C in the dark), and quench with DTT.
  • Dilute the urea concentration to <2M and digest first with LysC (3h, 25°C) followed by trypsin (overnight, 25°C).

• Peptide Clean-up and Pre-fractionation:

  • Desalt the resulting peptide mixture using a C18 solid-phase extraction (SPE) cartridge.
  • Separate the peptides using basic pH reversed-phase chromatography (as described in Section 4.1). Collect fractions and identify those containing the dominant K48-GG peptide via a test run. Pool the remaining "K48-depleted" fractions for downstream enrichment.

• diGLY Peptide Enrichment:

  • Use the anti-diGLY antibody for immunoaffinity purification. For the K48-depleted pooled fractions, use 1 mg of peptide material and 31.25 µg of antibody, incubating overnight at 4°C [3].
  • Wash the antibody-bound beads extensively and elute the diGLY-modified peptides with 0.15% trifluoroacetic acid (TFA).

• LC-MS/MS Analysis and Quantification:

  • Analyze the enriched peptides on a high-resolution LC-MS/MS system. Use a long, shallow C18 gradient (e.g., 90-180 min) for optimal separation.
  • Employ a DIA method for acquisition, using a customized window scheme optimized for the diGLY peptide precursor distribution [3].
  • Interrogate the data against a comprehensive in-house or public ubiquitinome spectral library for maximum site identification and accurate quantification.

By systematically implementing this multi-step strategy—centered on basic pH fractionation to manage high-abundance interferents—researchers can effectively overcome ion suppression and achieve a deeper, more quantitative understanding of the complex ubiquitin code.

The analysis of peptides and proteins by reversed-phase liquid chromatography coupled to mass spectrometry (RPLC-MS) is a cornerstone of modern proteomics and biopharmaceutical development. The selection of an acidic mobile phase modifier is a critical method development choice that directly creates a trade-off between chromatographic performance and MS sensitivity [48]. This application note details this balance, specifically within the context of basic pH reversed-phase chromatography for diGly peptide fractionation research. We provide a structured comparison of the two most prevalent modifiers, trifluoroacetic acid (TFA) and formic acid (FA), including quantitative data and detailed protocols to guide researchers in making an informed selection.

The Core Dilemma: Superior Separation vs. Optimal MS Sensitivity

In RPLC-MS of biomolecules, ion-pairing agents are added to the mobile phase to improve chromatographic performance. The fundamental challenge is that the most effective chromatographic agent, TFA, is a strong suppressor of the electrospray ionization (ESI) MS signal [49] [50].

• Trifluoroacetic Acid (TFA): TFA provides excellent chromatographic performance for peptides and proteins due to its strong ion-pairing capabilities. It suppresses the ionization of residual silanol groups on silica-based stationary phases, minimizing detrimental interactions with basic analytes and leading to sharp peaks and high resolution [48] [51]. However, its strong ion-pairing nature also leads to the formation of gas-phase ion pairs with protonated analytes, which severely suppresses the MS signal in positive ion mode [49] [48].
• Formic Acid (FA): Formic acid is a weaker ion-pairing agent. It is preferred for MS detection because it causes significantly less ion suppression, leading to greatly enhanced sensitivity [48]. The drawback is that its weaker ion-pairing strength and higher pH often result in broader peak shapes and poorer chromatographic resolution, particularly for basic analytes, due to effects like column overloading even with small sample masses [48].

The following diagram illustrates the logical workflow for selecting the appropriate acidic modifier based on the primary goal of the analysis.

Quantitative Comparison of TFA and Formic Acid

The table below summarizes the key characteristics of TFA and Formic Acid as mobile phase additives, drawing from comparative studies.

Table 1: Quantitative and Qualitative Comparison of TFA and Formic Acid

Characteristic	Trifluoroacetic Acid (TFA)	Formic Acid (FA)
Typical Concentration	0.05 - 0.1% (v/v) [51]	0.1 - 1.0% (v/v) [48]
Approximate pH (0.1% in H₂O)	~2.1 [51]	~2.7 [48]
Ion-Pairing Strength	Strong [48] [51]	Weak [48] [51]
Chromatographic Performance	Excellent; sharp peaks, high resolution [49] [48]	Good to Poor; broader peaks, potential for overloading [48]
MS Signal Suppression	Severe [49] [50] [48]	Moderate to Low [50] [48]
Primary MS Compatibility Issue	Forms stable ion-pairs with analytes, reducing gas-phase ion yield [49] [51]	Lower ion-pairing strength leads to less signal suppression [48]
Volatility	High, but can foul ion sources [51]	High, preferred for LC-MS [51]
UV Cut-Off	~210 nm (can cause high background) [51]	Lower than TFA

Recent research has identified potential alternative additives. A 2021 study found that difluoroacetic acid (DFA) could serve as a promising alternative to TFA for RPLC-MS, offering a better balance between chromatographic performance and MS sensitivity [50].

Detailed Experimental Protocols

Protocol 1: TFA-Free Nanoscale LC-MS for Histone Analysis

This protocol, adapted from a published study, demonstrates a TFA-free method for analyzing highly basic proteins like histones, offsetting the chromatographic performance loss by using nanoscale columns [49].

4.1.1 Research Reagent Solutions

Table 2: Essential Materials for TFA-free Histone Analysis

Item	Function / Description	Example / Source
Capillary/Nano C8 Column	Stationary phase for high-resolution separation of proteins.	0.1 mm × 150 mm C8, 3 μm, 300 Å [49]
Formic Acid (FA)	Volatile, MS-compatible ion-pairing agent.	HPLC Grade [49]
Acetonitrile (ACN)	Organic modifier for the mobile phase.	HPLC Grade [49]
Water	Aqueous component of the mobile phase.	HPLC Grade [49]
Nuclei Isolation Buffer (NIB)	For extracting nuclei from cells prior to histone acid extraction.	Contains Tris-HCl, NaCl, MgCl₂, NP-40, Spermine, Spermidine [49]
Sulfuric Acid (H₂SO₄)	For acidic extraction of histones from isolated nuclei.	0.4 M, ice-cold [49]
Acetone	For precipitating histones from the acidic extract.	Pre-chilled to -20°C [49]

4.1.2 Workflow Diagram

4.1.3 Step-by-Step Procedure

• Cell Lysis and Nuclei Isolation: Resuspend the cell pellet (e.g., 1.0 × 10⁸ human cancer cells) in 5 mL of ice-cold Nuclei Isolation Buffer (NIB). Incubate on ice for 5 minutes. Pellet the nuclei by centrifugation at 1,500 rpm for 15 minutes at 4°C. Wash the nuclei pellet with 5 mL of 10 mM Tris-HCl (pH 7.5) containing 150 mM NaCl [49].
• Histone Acid Extraction: Resuspend the washed nuclei pellet in 400 μL of ice-cold 0.4 M H₂SO₄. Incubate on ice for 30 minutes with occasional vortexing. Clarify the extract by centrifugation at 14,000 rpm for 15 minutes at 4°C. Transfer the supernatant to a new tube [49].
• Acetone Precipitation: Add chilled acetone to the supernatant to a final concentration of 80% (v/v). Precipitate the histones at -20°C overnight. Centrifuge the sample at maximum speed to pellet the histones. Wash the pellet with ice-cold acetone, air-dry, and dissolve in HPLC-grade water [49].
• TFA-free LC-MS Analysis:
  • Column: 0.1 mm i.d. × 150 mm C8 column (3 μm, 300 Å).
  • Mobile Phase: A: H₂O + 0.2% Formic Acid; B: Acetonitrile + 0.2% Formic Acid.
  • Flow Rate: 1 μL/min.
  • Gradient: Utilize a multi-segment linear-convex gradient, for example: 20-30% B over 20 min (curve 2), 30-35% B over 40 min (curve 4), 35-48% B over 13 min (linear) [49].
  • MS Settings: Heated capillary temperature: 175°C; Electrospray voltage: 2.0 kV. Acquire data in high-resolution mode (e.g., FTMS on an Orbitrap) [49].

Protocol 2: diGLY Peptide Enrichment and Analysis for Ubiquitylation Studies

This protocol outlines the steps for enriching and analyzing ubiquitin-modified peptides, which are central to diGly peptide fractionation research, using FA-based mobile phases for optimal MS sensitivity [2].

4.2.1 Research Reagent Solutions

Table 3: Essential Materials for diGLY Peptide Enrichment

Item	Function / Description	Example / Source
diGLY Motif Antibody	Immunoaffinity reagent for specifically enriching K-ϵ-GG-containing peptides.	PTMScan Ubiquitin Remnant Motif Kit [2]
SILAC Media	For metabolic labeling and quantitative proteomics.	DMEM lacking Lysine and Arginine [2]
Heavy Isotope Amino Acids	Incorporation of stable isotopes for quantification.	13C6,15N2 L-Lysine-2HCl and 13C6,15N4 L-Arginine-HCl [2]
Urea Lysis Buffer	Denaturing buffer for efficient cell lysis and protein extraction.	8 M Urea, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0 [2]
N-Ethylmaleimide (NEM)	Alkylating agent that covalently modifies cysteine residues to prevent disulfide bond formation.	Freshly prepared in ethanol, added to lysis buffer [2]
Protease Inhibitors	Prevent proteolytic degradation during sample preparation.	e.g., Complete Protease Inhibitor Cocktail [2]
LysC & Trypsin	Proteases for digesting proteins into peptides.	Sequencing grade [2]
SepPak tC18 Column	For desalting and cleaning up peptide digests prior to enrichment.	e.g., Waters 500 mg cartridge [2]

4.2.2 Workflow Diagram

4.2.2 Step-by-Step Procedure

• Cell Culture and Lysis:
  • Culture cells in SILAC media ("light" or "heavy") for several generations to achieve full metabolic labeling [2].
  • Lyse cells in Urea Lysis Buffer (8 M Urea, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0) supplemented with protease inhibitors and 5 mM NEM. Sonicate if necessary and clarify by centrifugation [2].
• Protein Digestion and Desalting:
  • Reduce and alkylate proteins (if not using NEM in the lysis buffer). Digest proteins first with LysC (1:100 enzyme-to-protein ratio) for 2-3 hours at room temperature, then dilute the urea concentration to 2 M and digest with trypsin (1:50 ratio) overnight at 37°C [2].
  • Acidify the digest with trifluoroacetic acid (TFA) to pH < 3 and desalt using a SepPak tC18 cartridge according to the manufacturer's instructions. Elute peptides with 50% ACN / 0.5% Acetic Acid and lyophilize [2].
• diGLY Peptide Immunoaffinity Enrichment:
  • Reconstitute the desalted peptide pellet in Immunoprecipitation (IAP) Buffer (e.g., 50 mM MOPS-NaOH, pH 7.3, 10 mM Na₂HPO₄, 50 mM NaCl).
  • Incubate the peptide solution with the diGLY motif antibody bead slurry for 1.5-2 hours at 4°C with gentle agitation.
  • Wash the beads 2-3 times with IAP Buffer, followed by 2-3 washes with HPLC-grade water.
  • Elute the enriched diGLY peptides with 0.1% TFA or 0.15% FA. The use of a strong acid like TFA here is for efficient elution from the antibody and is compatible with the subsequent desalting step before LC-MS [2].
• LC-MS Analysis of Enriched Peptides:
  • Desalt the enriched diGLY peptides using a StageTip or micro-SepPak column and lyophilize.
  • Basic pH RPLC Fractionation (Thesis Context): For deep coverage, fractionate the enriched peptides using basic pH reversed-phase chromatography (e.g., using a C18 column with a gradient of 10 mM ammonium bicarbonate, pH 10, vs. ACN). Pool fractions as required.
  • LC-MS/MS with FA: Analyze each fraction by nanoscale LC-MS/MS using a C18 column and a FA-based mobile phase gradient (e.g., 5-35% ACN in 0.1% FA over 90 minutes). Data-dependent acquisition on the MS is used to fragment diGLY-containing peptides for identification and SILAC-based quantification [2].

The choice between TFA and formic acid is a strategic decision that depends on the primary objective of the analysis. For applications where the highest chromatographic resolution is paramount and MS sensitivity is secondary, TFA remains the superior choice. Conversely, for sensitive detection and identification in discovery proteomics, particularly in diGly peptide research, formic acid is the necessary standard. As demonstrated in the protocols, this choice is embedded within a larger experimental framework, and the availability of alternative additives like DFA provides researchers with additional tools to fine-tune this critical balance for their specific needs.

Mitigating Ghost Peaks and Baseline Drift for Reproducible Gradient Elution

In the context of basic pH reversed-phase chromatography for the fractionation of diglycine (diGly) peptides, achieving a stable and reproducible chromatographic baseline is paramount. The identification of protein ubiquitination sites via mass spectrometry relies heavily on the analysis of peptides modified by a K-ε-GG remnant [2] [16]. The sensitivity and accuracy of this analysis are compromised by the presence of ghost peaks and baseline drift in the liquid chromatography (LC) system, particularly during gradient elution [52] [53]. These anomalies can obscure low-abundance diGly peptides, lead to misidentification of ubiquitination sites, and introduce variability that undermines quantitative assessments. This application note details the primary sources of these challenges and provides validated protocols for their mitigation, ensuring data integrity in deep ubiquitinome profiling.

Understanding the Challenges

Ghost Peaks

Ghost peaks are unexpected chromatographic signals that do not originate from the injected sample [53]. In diGly peptide analyses, they can be mistaken for low-level ubiquitination events, leading to incorrect biological interpretations. Their sources are predominantly contamination-based, arising from several areas of the HPLC system [53] [54].

Baseline Drift

Baseline drift refers to a steady upward or downward trend in the detector signal throughout a gradient run. This is a particular challenge in gradient methods where the mobile phase composition continuously changes, causing shifts in the refractive index and UV absorbance background [52]. Drift can obscure important peaks and compromise quantitative data quality, especially for low-intensity diGly peptides [52].

The following table summarizes the core problems and their impact on diGly peptide analysis.

Table 1: Core Chromatographic Challenges in diGly Peptide Analysis

Challenge	Definition	Primary Impact on diGly Research
Ghost Peaks	Unexpected chromatographic signals not from the injected sample [53].	Misidentification of false ubiquitination sites; overlap with genuine low-abundance diGly peaks.
Baseline Drift	A steady upward or downward trend in the baseline during a gradient run [52].	Compromised accuracy in quantifying diGly peptides; masking of low-intensity peaks.
Carryover	A specific type of ghost peak caused by the remnants of a previous sample injection [54].	Introduction of non-reproducible, false-positive signals across different samples.

Figure 1: A troubleshooting map outlining the primary causes, impacts, and mitigation strategies for common chromatographic issues in diGly peptide analysis.

Experimental Protocols for Diagnosis and Mitigation

Protocol 1: Systematic Diagnosis of Ghost Peaks

This protocol is designed to identify the source of ghost peaks in a structured manner.

Materials:

• HPLC-grade water and organic solvents (e.g., acetonitrile)
• Freshly prepared blank sample (mobile phase or sample solvent)
• Strong wash solvents (e.g., 50% isopropanol)

Procedure:

• Run a Blank Injection: Inject your blank sample and record the chromatogram using the same method as for your diGly peptide samples. This creates a baseline profile of the system itself [54].
• Analyze the Blank Chromatogram: Any peaks observed in the blank run are ghost peaks originating from the system, mobile phase, or vials [53] [54].
• Isolate the Source:
  • Mobile Phase: Replace all mobile phases with fresh, HPLC-grade solvents. Repeat the blank injection. If ghost peaks disappear, the original solvents were contaminated.
  • Sample Vials/Septae: Replace vials and septa with new ones and repeat the blank. If ghosts disappear, the source was leachates from the vials or septa.
  • Autosampler Carryover: Run a high-concentration standard, immediately followed by a blank injection. If peaks from the standard appear in the blank, carryover is the issue [54].
  • Column: Replace the analytical column with a new or known-good guard column. If ghost peaks persist, the column is likely not the primary source.
• Implement Corrective Action: Based on the findings above, clean or replace the contaminated component. This may include flushing the entire system with strong solvents, preparing new mobile phases, or replacing the column.

Protocol 2: Minimizing Baseline Drift in Gradient Elution for diGly Workflows

This protocol addresses drift caused by mobile phase mismatches and environmental factors, common in lengthy diGly peptide runs.

Materials:

• High-purity, fresh mobile phase additives (e.g., TFA, ammonium hydroxide)
• Inline degasser or helium sparging apparatus
• HPLC system with temperature-controlled column compartment

Procedure:

• Match Mobile Phase Absorbance: Check the UV absorbance of both the aqueous and organic mobile phases at your detection wavelength. Fine-tune their composition to closely match absorbance, which will minimize drift during the gradient [52].
• Employ a Static Mixer: Install a static mixer between the gradient pump and the injection valve. This ensures a more homogeneous mobile phase blend before it enters the column, reducing composition-based baseline fluctuations [52].
• Thorough Degassing: Use an inline degasser or helium sparge all mobile phases for 10-15 minutes before use. This prevents bubble formation in the detector flow cell, a common cause of sudden baseline spikes and drift [52].
• Control Temperature: Ensure the column compartment temperature is stable. For refractive index-sensitive detectors (a consideration even in UV for low-wavelength work), insulating exposed tubing and maintaining a stable lab temperature can reduce thermal noise [52].
• Run a Blank Gradient: Execute a full gradient method without injecting a sample. Use this chromatogram as a background trace to subtract from your sample runs during data processing, if your software allows [52].

Protocol 3: Comprehensive System Cleanliness and Maintenance

Prevention is the most effective strategy. This protocol should be performed regularly.

Materials:

• HPLC-grade water and solvents (isopropanol, acetonitrile)
• 1-2% phosphoric acid solution (for cleaning)
• Ceramic check valves (if using ion-pairing agents like TFA)

Procedure:

• Regular Flushing: At the end of each week or after running complex samples, flush the entire system (pump, injector, column compartment, detector) with a series of clean solvents. A typical sequence is:
  • 100% Water (15-20 column volumes)
  • 50% Isopropanol (15-20 column volumes)
  • 100% Storage-compatible solvent (e.g., 80% Acetonitrile) [52] [53].
• Autosampler Cleaning: Program the autosampler to perform extensive needle washes with a strong wash solvent (e.g., 50% isopropanol) between injections to minimize carryover [54].
• Check Valve Maintenance: If baseline noise is observed, particularly with TFA-based mobile phases, clean or replace pump check valves. Switching to ceramic check valves can significantly reduce noise [52].
• Use Guard Columns: Always use a guard column matched to your analytical column. This inexpensive component traps contaminants and preserves the life and performance of your more expensive analytical column [53] [54].

Research Reagent Solutions for diGly Peptide Analysis

The following table lists essential materials and reagents critical for successful and reproducible diGly peptide fractionation, with an emphasis on mitigating chromatographic artefacts.

Table 2: Key Research Reagents and Materials for Robust diGly Peptide Chromatography

Reagent/Material	Function & Rationale	Specifications for Optimal Performance
HPLC-Grade Solvents	High-purity mobile phase constituents to minimize UV-absorbing contaminants that cause baseline drift and ghost peaks [52] [53].	Purchase in small quantities; use fresh batches daily for critical gradient work [52].
High-Purity Additives (TFA)	Ion-pairing reagent for peptide separation. Low-quality TFA degrades, increasing UV background and drift [52].	Use high-purity, UV-cutoff rated TFA. For low wavelengths (< 220 nm), test different lots/brands.
Guard Column	Pre-column filter that traps particulate matter and contaminants, protecting the analytical column [53] [54].	Must be packed with the same stationary phase as the analytical column to prevent band broadening.
Ceramic Check Valves	HPLC pump components that ensure consistent solvent delivery. Superior for use with corrosive additives like TFA [52].	More resistant to corrosion and sticking than sapphire/ ruby valves, reducing baseline pulsation and noise.
Stable Isotope Amino Acids (SILAC)	For quantitative proteomics; allows mixing of test and control samples prior to lysis, normalizing pre-analytical variability [2] [16].	Use heavy Lysine (K8) and Arginine (R10); culture cells for >6 doublings for full incorporation [2].
diGly Motif-Specific Antibody	Immunoaffinity enrichment of K-ε-GG-modified peptides from complex digests prior to LC-MS/MS [2] [3].	Critical for deep ubiquitinome coverage. Use specified amount per mg of peptide input (e.g., 31.25 µg per 1 mg peptide) [3].

Data Presentation: Quantitative Impact of Optimized Workflows

Implementing the described protocols leads to tangible improvements in data quality. The following table synthesizes quantitative gains reported in the literature from optimized chromatographic and enrichment workflows.

Table 3: Quantitative Improvements from Optimized diGly Peptide Analysis Workflows

Optimization Parameter	Standard Performance	Optimized Performance	Key Enabling Factor(s)	Citation
diGly Peptides Identified (Single Shot)	~20,000 (DDA)	~35,000 (DIA)	Data-Independent Acquisition (DIA) & comprehensive spectral libraries [3].	[3]
Quantitative Reproducibility (CV < 20%)	15% of diGly peptides	45% of diGly peptides	Improved DIA quantification accuracy and reduced missing values [3].	[3]
diGly Peptides from Cell Lysate	Not specified	>23,000	Offline high-pH RP fractionation into 3 fractions prior to immuno-enrichment [5] [16].	[5] [16]
diGly Peptides from Tissue (Mouse Brain)	Challenging / Low Yield	Deep Coverage Achieved	Adapted lysis and fractionation protocol suitable for in vivo material [5] [16].	[5]

Figure 2: An optimized end-to-end workflow for deep ubiquitinome analysis, highlighting steps critical for minimizing artefacts and maximizing reproducibility. Key steps include basic-pH fractionation, specific diGly enrichment, and stable LC-MS/MS analysis [2] [3] [5].

The reproducibility of gradient elution in basic pH reversed-phase chromatography for diGly peptide research is inextricably linked to the stability of the chromatographic baseline and the absence of spurious peaks. By understanding the root causes of ghost peaks and baseline drift—primarily contamination, mobile phase issues, and inadequate system maintenance—researchers can implement the diagnostic and preventative protocols outlined herein. The consistent use of high-purity reagents, adherence to a rigorous maintenance schedule, and the integration of optimized workflows, such as pre-enrichment fractionation and DIA mass spectrometry, are proven to significantly enhance the depth, accuracy, and reliability of ubiquitinome studies. This systematic approach to troubleshooting and quality control ensures that the resulting data robustly reflects biological reality, thereby strengthening downstream conclusions in drug development and basic research.

Optimizing Sample Input, Column Loading, and Gradient Steepness for Maximum diGly Peptide Yield

Within the framework of a broader thesis on basic pH reversed-phase chromatography for diGly peptide fractionation, this document provides a detailed protocol for optimizing critical parameters to maximize the yield of ubiquitin-derived diglycine (diGly) peptides. The identification of protein ubiquitination sites via mass spectrometry (MS) is a cornerstone of modern proteomics, enabling researchers to decipher critical regulatory pathways in cellular signaling and drug mechanisms [55]. The foundational step for this analysis is the immunoaffinity enrichment of diGly-containing peptides following tryptic digestion of protein samples [16].

The depth and reliability of the subsequent ubiquitinome analysis are highly dependent on the chromatographic resolution and recovery of these peptides prior to enrichment and MS analysis. This application note systematically evaluates and optimizes three key interconnected parameters—sample input amount, column loading capacity, and gradient steepness—within a high-pH reversed-phase fractionation scheme. The optimized methods detailed herein are designed to be directly applicable for researchers and drug development professionals seeking to achieve comprehensive system-wide coverage of ubiquitination events.

Key Principles of diGly Peptide Analysis

The analysis of the ubiquitinome relies on the specific properties of ubiquitin and the peptides generated for mass spectrometry.

• diGly Remnant Motif: During standard tryptic digestion of ubiquitinated proteins, the C-terminal end of ubiquitin is cleaved, leaving a characteristic diglycine (Gly-Gly) remnant attached via an isopeptide bond to the ε-amino group of the modified lysine residue on the substrate peptide. This K-ε-GG motif serves as a specific handle for enrichment [16] [55].
• Role of High-pH Reversed-Phase Chromatography: Fractionating complex peptide mixtures using high-pH reversed-phase (RP) chromatography as a first-dimensional separation significantly reduces sample complexity. This is orthologous to the common low-pH RP separation used in the second dimension (online with MS), leading to a greater dynamic range and higher proteome coverage in shotgun proteomics analyses [19]. This orthogonality is crucial for resolving the deep ubiquitinome.

Experimental Optimization for Maximum diGly Yield

The following diagram illustrates the comprehensive optimized workflow for deep ubiquitinome analysis, from sample preparation to data acquisition.

Optimizing Sample Input and Column Loading

Determining the correct amount of peptide material to load onto the fractionation column is critical. Overloading saturates the column's binding capacity, leading to poor resolution and peptide loss, while underloading fails to utilize the column's separation power, reducing the depth of analysis.

Protocol: Determining Optimal Sample Load

• Column Preparation: Use a high-pH stable C18 reversed-phase spin column (e.g., from the Pierce High pH Reversed-Phase Peptide Fractionation Kit). Condition the column according to the manufacturer's instructions [30].
• Sample Preparation: Prepare a complex peptide digest from a cell line (e.g., HEK293, HeLa, or U2OS). Treating cells with a proteasome inhibitor (e.g., 10 µM MG132 for 4 hours) prior to lysis will increase the abundance of ubiquitinated proteins and thus diGly peptides, providing a more robust signal for optimization [3] [16].
• Loading Test: Create a dilution series of the peptide digest. A recommended starting range is 10 µg to 100 µg of total peptides per fractionation column, as this is the effective operating range for many commercial spin columns [30].
• Fractionation and Analysis: Fractionate each loading amount using an optimized high-pH acetonitrile gradient. Pool the fractions, perform diGly immunoenrichment, and analyze equal percentages of each final sample by LC-MS/MS.
• Assessment: The optimal load is identified as the point where the number of unique diGly peptide identifications plateaus or begins to decrease. A systematic study on a 75 µm I.D. x 12 cm C18 column found that the column was nearly saturated with ~1 µg of a complex yeast peptide digest, indicating that capacity is highly dependent on column geometry and packing [56].

Table 1: Optimization of Sample Input and Column Loading

Parameter	Tested Range	Optimal Value	Key Observation	Source
Total Peptide Load	10 - 100 µg	~1 µg (on a 75µm x 12cm column)	Column saturation occurs near 1 µg; higher loads reduce identifications.	[56]
diGly Enrichment Input	Titration of peptide material from 1 mg	1 mg total peptides	Optimal yield for deep coverage when using 31.25 µg antibody.	[3]
Proteasome Inhibition	10 µM MG132 for 4 h	Recommended	Increases diGly peptide abundance, crucial for optimization signal.	[3] [16]

Optimizing Gradient Steepness and Length

The chromatographic gradient controls the elution of peptides based on hydrophobicity. A longer, shallower gradient provides higher resolution, separating more peptide species, while a steeper, shorter gradient is faster but may co-elute peptides.

Protocol: Systematic Gradient Optimization

• Fixed Parameters: Keep the sample load and column flow rate constant. For a 0.5 mL/min flow rate on an analytical column, a flow rate of ~0.2 µL/min is typical for nanoflow columns (75 µm I.D.) [56].
• Gradient Length: Test gradients of different lengths (e.g., 40 min, 86 min, 160 min) for the same acetonitrile range (e.g., 2% to 48%). Research indicates that the optimal gradient length is dependent on the sample amount. For instance, a 160-minute gradient was optimal for 1 µg of a yeast peptide mix, whereas a 40-minute gradient sufficed for 10 ng of the same sample [56].
• Gradient Range: Determine the effective elution window for diGly peptides. A broad gradient (e.g., 5-50% or 2-48% acetonitrile) is recommended to capture the wide hydrophobicity range of tryptic peptides [6] [56]. Coupling this with a linearly decreasing gradient of acidic modifier can improve baseline stability [6].
• Evaluation: Analyze the results based on the total number of unique diGly peptides identified, peak width (narrower peaks indicate better resolution), and the evenness of peptide distribution across fractions.

Table 2: Optimization of Chromatographic Gradient Conditions

Parameter	Tested Range	Optimal Value	Key Observation	Source
Gradient Length	40 - 160 min	160 min (for 1 µg load)	Longer gradients improve resolution for complex samples.	[56]
Gradient Range	2 - 48% AcN	13 - 32% AcN (effective elution)	The majority of peptides elute within this range.	[56]
Flow Rate	Not specified	~0.2 µL/min (nanoflow)	Optimal flow rate for 75µm I.D. x 12cm columns.	[56]
Fraction Concatenation	Adjacent vs. Non-adjacent	Non-adjacent pooling	Increases orthogonality and identifications by ~80% for peptides.	[19]

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents and Materials for diGly Peptide Analysis

Item	Function/Application	Example/Catalog
diGly Remnant Motif Antibody	Immunoaffinity enrichment of K-ε-GG modified peptides.	PTMScan Ubiquitin Remnant Motif Kit [3] [16]
High-pH RP Fractionation Kit	Offline fractionation to reduce sample complexity; spin column format.	Pierce High pH Reversed-Phase Peptide Fractionation Kit (Cat. No. 84868) [30]
Proteasome Inhibitor	Increases cellular levels of ubiquitinated proteins.	MG132, Bortezomib [3] [16]
C18 Solid-Phase Extraction Cartridge	Peptide cleanup and desalting after digestion.	Vydac Bioselect C18 cartridge [56]
Mass Spectrometer	High-sensitivity identification and quantification of peptides.	Orbitrap-based platforms (e.g., LTQ-Orbitrap) [3] [56]

Discussion and Concluding Remarks

The systematic optimization of sample input, column loading, and gradient parameters is not a one-time exercise but a fundamental requirement for achieving maximum depth in ubiquitinome analyses. The data presented demonstrate that these parameters are deeply interdependent; the ideal gradient length, for instance, is a function of the sample load [56]. Furthermore, the adoption of fraction concatenation after high-pH RP fractionation dramatically improves the orthogonality of the two-dimensional separation compared to traditional strong-cation exchange (SCX), leading to significant gains in peptide and protein identifications [19].

The integration of these optimized wet-lab protocols with advanced mass spectrometry acquisition methods, such as Data-Independent Acquisition (DIA), represents the current state-of-the-art. DIA has been shown to double the number of diGly peptides identified in a single measurement compared to traditional Data-Dependent Acquisition (DDA), while also providing superior quantitative accuracy and reproducibility [3]. By adhering to the detailed protocols and principles outlined in this application note, researchers can robustly and reproducibly uncover the deep ubiquitinome, paving the way for novel discoveries in basic biology and drug development.

Benchmarking bRPLC Performance: Reproducibility, Quantification Accuracy, and Comparative Workflows

Within the context of advanced ubiquitinome research, the depth and reliability of quantitative data are paramount. This application note details a sensitive workflow that integrates basic pH reversed-phase (bRP) chromatography for peptide fractionation with data-independent acquisition (DIA) mass spectrometry, specifically tailored for the analysis of endogenous diGly-modified peptides [8]. The transition from traditional data-dependent acquisition (DDA) to optimized DIA methods marks a significant progression in the field, effectively addressing perennial challenges such as low stoichiometry of modification, inconsistent data completeness, and quantitative inaccuracy in single-run analyses [8] [57]. We demonstrate that this optimized DIA-based workflow doubles the number of diGly peptide identifications in a single measurement while significantly improving quantitative accuracy and reproducibility, thereby providing a robust tool for systems-wide investigations of ubiquitin signaling in drug development [8].

Key Quantitative Performance Gains of DIA vs. DDA

The implementation of a DIA-based workflow for diGly proteome analysis yields substantial, quantifiable improvements over traditional DDA methods. These gains are evident across three critical performance metrics: identification depth, quantitative reproducibility, and data completeness.

• Identification Depth: In single measurements of proteasome inhibitor-treated cells (HEK293), the optimized DIA workflow identified 35,111 ± 682 distinct diGly sites [8]. This represents a doubling of identification depth compared to previous DDA reports and underscores the power of DIA for comprehensive ubiquitinome profiling. Notably, even without a spectral library ("direct DIA"), the method identified over 26,000 diGly sites, highlighting its inherent sensitivity [8].
• Quantitative Reproducibility: The DIA workflow demonstrates exceptional quantitative precision. Technical replicates showed that 45% of all quantified diGly peptides had a coefficient of variation (CV) below 20%, and 77% had a CV below 50% [8]. This high level of reproducibility is crucial for confidently detecting subtle changes in ubiquitination in response to stimuli or drug treatments.
• Data Completeness: A major advantage of DIA is the drastic reduction of missing values across multiple samples. In benchmark comparisons, prioritized acquisition strategies, a refinement of DIA, have been shown to increase data completeness for challenging peptides by over 170% compared to standard DDA [20]. This ensures more robust statistical analysis and a more complete picture of the ubiquitinome across biological replicates.

Table 1: Summary of Quantitative Performance Gains with DIA for diGly Proteome Analysis

Performance Metric	DIA Performance	Context vs. DDA
DiGly Sites (Single Run)	35,111 ± 682 [8]	Double the number identified by DDA [8]
Quantitative Reproducibility (CV < 20%)	45% of peptides [8]	Marked improvement over DDA's stochasticity
Data Completeness	>90% for proteins with prioritization [20]	171% increase for challenging peptides [20]
Spectral Library Size	>90,000 diGly peptides [8]	Enables deep, consistent single-run identification

Experimental Protocols

Basic pH Reversed-Phase Chromatography for DiGly Peptide Fractionation

Objective: To deeply fractionate a complex peptide mixture from cell lysates to construct a comprehensive spectral library for DIA analysis [8].

Materials:

• Cell Lines: HEK293 and U2OS cells.
• Reagents: Proteasome inhibitor (e.g., MG132), lysis buffer, trypsin, Lys-C, C18 solid-phase extraction tips/columns, HPLC-grade solvents (water, acetonitrile), ammonium bicarbonate (or ammonium formate) for basic pH mobile phase.
• Equipment: HPLC system equipped with a reversed-phase column (e.g., C18, 1.0 mm x 150 mm).

Procedure:

• Cell Culture and Treatment: Culture HEK293 and U2OS cells. Treat with 10 µM MG132 for 4 hours to inhibit the proteasome and enrich for ubiquitinated proteins [8].
• Protein Extraction and Digestion: Lyse cells and extract proteins. Digest the proteins using a combination of Lys-C and trypsin to generate peptides with C-terminal diGly remnants [8] [58].
• Peptide Clean-up: Desalt the resulting peptides using C18 solid-phase extraction.
• bRP Fractionation:
  • Sample Load: Dissolve the peptide pellet in a basic pH mobile phase (e.g., pH 10) with a low concentration of organic modifier [59].
  • Chromatography Setup: Set up the HPLC with a C18 column. Use a mobile phase comprising a constant low concentration of organic modifier while applying a recurring gradient of pH in the mobile phase [59].
  • Fraction Collection: Separate peptides using the bRP method. Collect a large number of fractions (e.g., 96) and subsequently concatenate them into a smaller number of pools (e.g., 8-9) to reduce sample complexity while maintaining high resolution [8]. Note: Due to its extreme abundance, the K48-linked ubiquitin-chain derived diGly peptide should be isolated and processed separately to prevent competition during subsequent enrichment steps [8].

Immunoaffinity Enrichment of DiGly Peptides

Objective: To selectively isolate diGly-containing peptides from the fractionated peptide pools using anti-diGly remnant motif antibodies.

Materials:

• Antibody: Anti-K-ε-GG Ubiquitin Remnant Motif Kit [8].
• Equipment: Microcentrifuge, filter tips, stage tips with C18 material.

Procedure:

• Antibody Binding: For each fraction pool, incubate 1 mg of peptide material with 31.25 µg of anti-diGly antibody conjugated to agarose beads. Perform the incubation for 2 hours at 4°C with rotation [8] [58].
• Washing: Pellet the beads by centrifugation and carefully remove the supernatant. Wash the beads multiple times with ice-cold immunoaffinity purification (IAP) buffer, followed by several washes with purified water to remove non-specifically bound peptides [58].
• Elution: Elute the bound diGly peptides from the beads using 0.15% trifluoroacetic acid (TFA) [58].
• Desalting and Concentration: Desalt the eluted peptides using C18 stage tips. Concentrate the peptides via vacuum centrifugation for downstream MS analysis [58].

Optimized DIA Mass Spectrometry Analysis

Objective: To acquire comprehensive and quantitative data from enriched diGly peptides in a single-run analysis.

Materials:

• Mass Spectrometer: Orbitrap-based mass spectrometer (e.g., Orbitrap Fusion Lumos) [8].
• LC System: Nanoflow liquid chromatography system.

Procedure:

• Spectral Library Generation: Analyze the fractionated and enriched diGly peptide pools using a standard DDA method to build an extensive spectral library. This library should contain over 90,000 diGly peptides to enable robust matching in DIA runs [8].
• DIA Method Optimization:
  • Precursor Isolation Windows: Implement an optimized DIA method with 46 variable-width precursor isolation windows to cover the desired m/z range efficiently [8].
  • MS2 Resolution: Set the MS2 scan resolution to 30,000 to improve peptide identification [8].
  • Cycle Time: Balance the number of windows and scan resolution to achieve a cycle time that allows for sufficient sampling of chromatographic peaks [8].
• Sample Analysis: Inject only 25% of the total enriched diGly material onto the LC-MS system. Perform chromatography using a standard nanoflow LC gradient. Acquire data using the optimized DIA method [8].
• Data Analysis: Use specialized DIA software tools (e.g., OpenSWATH, DIA-NN) to match the acquired data against the pre-generated spectral library. Employ a hybrid library approach, merging the DDA library with a direct DIA search, to maximize peptide identifications [8] [57].

Workflow and Signaling Visualization

The following diagram outlines the complete end-to-end process for deep ubiquitinome analysis using bRP fractionation and DIA MS.

Diagram 1: Workflow for diGly analysis.

DIA vs. DDA Acquisition Logic

This diagram contrasts the fundamental acquisition strategies of DDA and DIA, highlighting the source of performance gains.

Diagram 2: DIA vs DDA logic.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful execution of this advanced ubiquitinome profiling workflow relies on several key reagents and materials. The following table details these critical components and their specific functions within the protocol.

Table 2: Key Research Reagent Solutions for DIA Ubiquitinome Analysis

Item	Function/Application	Key Characteristic
Anti-K-ε-GG Ubiquitin Remnant Motif Kit	Immunoaffinity enrichment of diGly-modified peptides from complex peptide mixtures [8].	High-specificity antibody for the ubiquitin-derived diGly remnant.
Proteasome Inhibitor (MG132)	Treatment of cells prior to lysis to block degradation of ubiquitinated proteins, thereby increasing their abundance for analysis [8].	Enhances yield of ubiquitinated substrates.
Basic pH Reversed-Phase Column	High-resolution fractionation of complex peptide digests based on hydrophobicity and isoelectric point (pI) under basic conditions [8] [59].	Enables deep library generation.
Lys-C/Trypsin Enzymes	Sequential digestion of proteins to generate peptides with C-terminal diGly remnants for antibody recognition [58].	Specific cleavage to expose the diGly motif.
Orbitrap-based Mass Spectrometer	High-resolution and high-mass-accuracy mass analyzer for performing both DDA library building and optimized DIA acquisitions [8].	Essential for sensitive, reproducible DIA.
DIA Data Analysis Software (e.g., DIA-NN, OpenSWATH)	Computational tools for matching DIA MS2 spectra to peptide sequences in a spectral library and for quantitative analysis [57].	Critical for interpreting complex DIA data.

Within the field of ubiquitin proteomics, the depth of analysis is a primary determinant of experimental success. The choice between a fractionated approach using basic pH reversed-phase liquid chromatography (bRPLC) and a single-shot analysis represents a critical methodological crossroad, balancing comprehensiveness against throughput, sample requirement, and complexity. This application note provides a direct, quantitative comparison of these two strategies for the identification of ubiquitin modification sites, specifically those marked by the tryptic diglycine (diGly) remnant. Framed within a broader thesis on optimizing bRPLC for diGly research, this document delivers detailed protocols and data to guide researchers, scientists, and drug development professionals in selecting the appropriate methodology for their specific experimental goals.

Key Comparison: bRPLC Fractionation vs. Single-Shot diGly Analysis

The following table summarizes the core performance characteristics of the two methods based on current literature, providing a clear basis for strategic decision-making.

Table 1: Direct comparison of bRPLC fractionation and single-shot analysis for diGly proteomics.

Feature	bRPLC Fractionation	Single-Shot Analysis
Typical Scale	Micro-scale (5-20 μg peptide material) [14] to larger amounts (e.g., 1 mg) [8]	Standard scale (e.g., 250 μg from 1 mg input) [8]
Depth of Coverage	High; >67,000 diGly peptides identified in fractionated library [8]	Moderate; ~35,000 diGly peptides with optimized DIA [8]
Quantitative Accuracy	High, but can vary with fractionation depth and quantification method (e.g., iTRAQ, label-free) [14]	High with DIA (Data-Independent Acquisition); median CV ~20% [8]
Sample Throughput	Low; requires extensive instrument time for multiple fractions	High; rapid analysis of a single sample
Technical Complexity	High; involves peptide fractionation and concatenation steps [8] [5]	Low; streamlined workflow post-enrichment
Optimal Use Cases	In-depth ubiquitinome mapping, discovery-phase studies, low-abundance site identification [5]	High-throughput screening, temporal signaling studies, quantitative comparisons of multiple conditions [8]

Detailed Experimental Protocols

Protocol for Micro-Scale bRPLC Fractionation

This protocol is adapted for processing small sample amounts (e.g., 5-20 μg of peptides) prior to diGly immunopurification, maximizing depth from limited material [14] [5].

Materials

• Micro-columns: C18 StageTips (e.g., Thermo Fisher Scientific) [14]
• bRPLC Resin: Jupiter C18 material (5 μm, Phenomenex) [14]
• Elution Buffers: 100 mM NH₄HCO₃, pH 8.0, with increasing ACN concentrations (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 90%) [14]
• Equipment: Benchtop centrifuge

Procedure

• Column Preparation: Pack a C18 StageTip by adding a slurry of C18 resin in acetonitrile. Centrifuge (3,000 × g, 3 min) to form a uniform disk [14].
• Column Activation and Equilibration:
  • Wash with 100 μL of 100% acetonitrile via centrifugation.
  • Equilibrate with 100 μL of 100 mM NH₄HCO₃, pH 8.0 [14].
• Sample Loading: Dissolve the peptide sample in equilibration buffer and load onto the column. Centrifuge to pass the sample through.
• Step-Gradient Elution: Elute peptides sequentially using 100 μL of each elution buffer (5%, 10%, 15%, 20%, 25%, 30%, 90% ACN in 100 mM NH₄HCO₃, pH 8.0). Collect each eluate as a separate fraction [14].
• Fraction Concatenation: For deeper analysis, multiple primary fractions can be pooled (concatenated) to reduce the total number of LC-MS/MS runs. For example, 96 fractions can be pooled into 8 final samples [8].
• Vacuum Concentration: Concentrate the fractions to dryness via vacuum centrifugation before resuspension for diGly immunopurification [5].

Protocol for Single-Shot diGly Analysis with Optimized DIA

This protocol leverages data-independent acquisition (DIA) for high-depth analysis without pre-fractionation, ideal for quantitative studies [8].

Materials

• Lysis Buffer: 8M Urea, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, supplemented with protease inhibitors (e.g., Complete Protease Inhibitor Cocktail) and 5 mM N-Ethylmaleimide (NEM) to inhibit deubiquitinating enzymes [2].
• Digestion Enzymes: LysC and trypsin (e.g., Trypsin Gold, Promega) [2].
• diGLY Antibody: PTMScan Ubiquitin Remnant Motif (K-ε-GG) Kit (Cell Signaling Technology) or equivalent [2] [8].
• Desalting Columns: SepPak tC18 reverse-phase columns (Waters) [2].

Procedure

• Cell Lysis and Protein Digestion:
  • Lyse cells or tissue in denaturing lysis buffer containing NEM.
  • Reduce and alkylate proteins. Dilute the urea concentration to 1-2M and digest proteins first with LysC (Wako) followed by trypsin (Sigma) [2].
• Peptide Desalting: Desalt the resulting peptide mixture using a C18 SepPak column according to the manufacturer's instructions. Dry the peptides by vacuum centrifugation [2].
• diGly Peptide Immunopurification:
  • Resuspend peptides in immunoaffinity purification (IAP) buffer.
  • Incubate with the anti-diGly remnant antibody (e.g., 31.25 μg antibody per 1 mg peptide input) conjugated to beads for a recommended duration [8].
  • Wash the beads extensively with IAP buffer and then with water to remove non-specifically bound peptides.
• On-Bead Cleanup and Elution: Using a filter plug to retain beads during wash steps increases specificity. Elute diGly peptides with a low-pH buffer such as 0.15% TFA [5].
• LC-MS/MS Analysis with Optimized DIA:
  • MS Instrument: Orbitrap mass spectrometer.
  • DIA Method: Utilize an optimized DIA method with 46 precursor isolation windows covering the m/z range 350-1200, and MS2 spectra acquired at a resolution of 30,000. This method is tailored for the higher charge states typical of diGly peptides [8].
  • Library Use: For maximum identifications, use a project-specific or publicly available comprehensive spectral library or a hybrid library generated from DDA and direct DIA searches [8].

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key reagents and materials for diGly proteomics workflows.

Item	Function/Description	Example Product/Catalog
diGLY Motif Antibody	Immunoaffinity enrichment of K-ε-GG-containing peptides following trypsin digestion.	PTMScan Ubiquitin Remnant Motif Kit (CST) [2] [8]
LysC & Trypsin	Sequential digestion of proteins; LysC improves efficiency before tryptic cleavage.	LysC (Wako #125-02543); Trypsin (Sigma #T1426) [2]
N-Ethylmaleimide (NEM)	Deubiquitinase (DUB) inhibitor; preserves ubiquitin signals during lysis by alkylating cysteine residues.	Prepare fresh in ethanol [2]
C18 StageTips	Micro-scale solid-phase extraction for sample cleanup and basic-pH reversed-phase fractionation.	Thermo Fisher Scientific SP301 [14]
SILAC Media	For metabolic labeling and quantitative proteomics; enables precise ratio-based quantification.	DMEM lacking Lys/Arg (Thermo Fisher #88364) with heavy isotopes (K8/R10) [2]
Urea Lysis Buffer	Efficient cell lysis and protein denaturation while inhibiting enzyme activity.	8M Urea, 150mM NaCl, 50mM Tris-HCl, pH 8 [2]

Workflow Visualization

Diagram 1: Core diGly proteomics workflow with strategic decision point.

The decision between bRPLC fractionation and single-shot analysis is not a matter of identifying a superior technique, but rather of aligning methodology with scientific objective. For the most comprehensive, in-depth mapping of the ubiquitinome—particularly from complex samples or for the discovery of low-abundance modifications—bRPLC fractionation remains the gold standard. Conversely, for high-throughput, quantitative studies of ubiquitin signaling dynamics across multiple conditions, the optimized single-shot DIA approach offers an unparalleled balance of depth, accuracy, and speed. By implementing the detailed protocols and considerations outlined in this document, researchers can effectively harness the power of both strategies to advance our understanding of the ubiquitin-modified proteome.

The study of ubiquitinomes, which involves the system-wide analysis of protein ubiquitination, presents significant challenges due to the low stoichiometry and dynamic nature of modified peptides. This application note demonstrates that the combination of basic pH reversed-phase liquid chromatography (bRPLC) for peptide fractionation with Data-Independent Acquisition (DIA) mass spectrometry represents a superior approach for ubiquitinome studies compared to traditional Data-Dependent Acquisition (DDA) methods. We present comprehensive experimental data and detailed protocols showing that bRPLC-DIA delivers enhanced quantitative accuracy, improved reproducibility, and greater coverage of diGly-modified peptides—the signature tryptic peptides of ubiquitination. This integrated workflow provides researchers with a robust platform for discovering ubiquitination-dependent regulatory mechanisms in biological systems and drug development contexts.

Ubiquitinome profiling requires exceptional analytical sensitivity to detect low-abundance diGly-modified peptides against a complex background of unmodified peptides. Traditional DDA methods, which selectively fragment the most abundant precursor ions, often miss these critical modified peptides due to their low stoichiometry. The bRPLC-DIA workflow addresses this fundamental limitation through orthogonal separation and comprehensive data acquisition strategies.

Basic pH reversed-phase chromatography (bRPLC) provides high-resolution fractionation of complex peptide mixtures based on hydrophobicity at alkaline pH, offering excellent orthogonality to subsequent acidic pH reverse-phase separations coupled directly to mass spectrometry [13]. This two-dimensional separation significantly reduces sample complexity, thereby enhancing the detection of low-abundance diGly peptides. Data-Independent Acquisition (DIA) complements this approach by systematically fragmenting all ions within predetermined m/z windows, eliminating the stochastic sampling limitations of DDA and ensuring comprehensive detection of ubiquitinated peptides [60] [61].

Comparative Performance Data: bRPLC-DIA vs. Traditional DDA

Comprehensive Quantitative Comparison

The following tables summarize extensive experimental data comparing the performance of bRPLC-DIA versus traditional DDA workflows in proteomic studies, with particular relevance to ubiquitinome applications.

Table 1: Overall Performance Metrics Comparison Between DIA and DDA

Performance Metric	DIA Method	DDA Method	Improvement	Citation
Proteins Identified	7,740	5,159	+50.1%	[61]
Unique Proteins in Tear Fluid	701	396	+77.0%	[62]
Peptides Identified	2,444	1,447	+68.9%	[62]
Data Completeness	78.7%	42.0%	+36.7%	[62]
Quantitative Coverage	98-99%	92-95%	+5.2%	[61]
Reproducibility (CV)	<10%	>15%	>5% reduction	[61] [62]
Intra-group Correlation	>0.98	0.96-0.98	Improved	[61]

Table 2: Performance Advantages Specific to bRPLC Fractionation

Parameter	bRPLC-DIA Performance	Significance for Ubiquitinomics	Citation
Identification Gain	+43.6% more cross-linked peptides vs. conventional SCX	Enhanced detection of low-abundance modified peptides	[13]
Sample Requirement	Effective with 5-20 μg samples	Enables analysis of limited clinical specimens	[14]
Protein Identifications	~3,200 to 4,000 proteins from minimal material	Comprehensive coverage from small samples	[14]
Reproducibility	CV of 1.9-8.9% in replicate analyses	High quantitative precision for differential analysis	[14]
Sensitivity Increase	4.5-fold improvement in targeted quantitation	Crucial for detecting low-stoichiometry ubiquitination	[14]

Key Advantages for Ubiquitinome Studies

The bRPLC-DIA workflow demonstrates particular benefits for ubiquitinome studies:

• Enhanced Detection of Low-Abundance Peptides: DIA's comprehensive acquisition method fragments all analyte ions within predefined m/z ranges, ensuring detection of low-stoichiometry diGly peptides that DDA typically misses due to its intensity-based selection bias [60] [14]. This is critical in ubiquitinomics where modified peptides represent a minute fraction of the total proteome.

• Superior Quantitative Accuracy and Reproducibility: DIA provides more consistent results across replicates with lower coefficients of variation (<10% vs. >15% for DDA), enabling more reliable quantification of ubiquitination dynamics in response to cellular stimuli or drug treatments [61] [62].

• Increased Data Completeness: With 78.7% data completeness for proteins compared to 42.0% with DDA, bRPLC-DIA significantly reduces missing values in ubiquitinome datasets, thereby enhancing statistical power and reducing the need for imputation methods that can introduce artifacts [62].

Experimental Protocols

Micro-Scale bRPLC Fractionation for diGly Peptide Enrichment

The following protocol describes an optimized micro-scale bRPLC method for fractionating complex peptide mixtures prior to diGly peptide enrichment, adapted for limited biological samples [14]:

Materials and Reagents:

• Jupiter C18 material (5 μm particle diameter, Phenomenex)
• C18 Stage Tips (ThermoFisher Scientific)
• Ammonium bicarbonate (NH₄HCO₃, 100 mM, pH 8.0)
• Acetonitrile (HPLC grade)
• Deionized water

Procedure:

• Column Preparation: Add slurry of 2 mg Jupiter C18 material to commercially produced C18 StageTips. Wash with 100 μL 100% acetonitrile followed by 100 μL equilibration buffer (100 mM NH₄HCO₃, pH 8.0) using benchtop centrifugation (3,000 × g for 3 min).

• Sample Loading: Dissolve digested peptide samples in 100 μL equilibration buffer and load onto prepared columns. Centrifuge at 3,000 × g for 3 min to bind peptides.

• Step-Gradient Elution: Elute peptides using 100 μL portions of 7 different elution buffers with increasing acetonitrile concentrations (5%, 10%, 15%, 20%, 25%, 30%, 90% acetonitrile in 100 mM NH₄HCO₃, pH 8.0). Collect each fraction separately via centrifugation at 3,000 × g for 3 min.

• Sample Preparation for MS Analysis: Concentrate fractions to near-dryness using a vacuum concentrator and reconstitute in 3% aqueous acetonitrile containing 0.1% formic acid for LC-MS/MS analysis.

This micro-bRPLC platform efficiently processes 5-20 μg samples with minimal handling, making it ideal for clinical specimens where material is limited. The high orthogonality of bRPLC with subsequent acidic pH reverse-phase LC-MS significantly reduces sample complexity, enhancing detection of low-abundance diGly peptides [14].

DIA Mass Spectrometry Acquisition Parameters

For comprehensive ubiquitinome analysis, the following DIA parameters are recommended:

• Chromatography Conditions:

  • Column: 30 cm × 75 μm packed with Jupiter 3 μm, 100 Å pore size C18 beads
  • Mobile Phase A: 0.1% formic acid in deionized water
  • Mobile Phase B: 0.1% formic acid in acetonitrile
  • Gradient: 3% B to 5% B over 3 min, 5% B to 32% B over 75 min, 30% B to 60% B over 5 min, to 95% B over 6 min
  • Flow Rate: 450 nL/min [14]

• Mass Spectrometry Settings:

  • Full MS scans: m/z 350-1200 at resolution 60,000
  • DIA Windows: 20-40 m/z windows covering the entire mass range
  • Automatic Gain Control (AGC): 5×10⁵
  • Normalization: Equalize Medians for MS2 level data [63]

• Data Processing:

  • Use DIA-NN v1.8.2 or similar specialized DIA software with the following settings: unimod4; qvalue 0.01; cut K, R, !*P; reanalyze; smart-profiling [63]
  • For handling missing values, consider retention time boundary imputation methods like Nettle, which imputes RT boundaries rather than quantitations, integrating chromatographic signal within imputed boundaries for more accurate quantification of low-abundance peptides [63]

Visualizing the bRPLC-DIA Workflow and Advantages

bRPLC-DIA Workflow for Ubiquitinome Analysis

DDA vs. DIA Acquisition Comparison

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagents and Materials for bRPLC-DIA Ubiquitinome Studies

Item	Function/Application	Example Specifications	Citation
Jupiter C18 Material	Reverse-phase chromatography medium for bRPLC fractionation	5 μm particle diameter, 100 Å pore size	[14]
C18 StageTips	Micro-column platform for bRPLC fractionation	Disposable pipette tips with integrated frits	[14]
Ammonium Bicarbonate	Buffering component for basic pH mobile phases	100 mM, pH 8.0	[14]
Trypsin (Gold)	Proteolytic digestion of protein samples	Sequencing grade, 1:50 enzyme:substrate ratio	[14]
DIA-NN Software	Computational analysis of DIA mass spectrometry data	Version 1.8.2 with smart-profiling	[63]
Skyline Software	Targeted mass spectrometry data analysis	For peptide quantification and RT alignment	[63]
Nettle Tool	Retention time boundary imputation for missing values	Open-source implementation on GitHub	[63]
diGly Antibody	Immunoaffinity enrichment of ubiquitinated peptides	Anti-K-ε-GG antibody for peptide pull-down	-

The bRPLC-DIA workflow represents a significant advancement for ubiquitinome studies, addressing the critical challenges of detecting low-stoichiometry modified peptides and providing robust quantitative data. The method's enhanced sensitivity, reproducibility, and quantitative accuracy make it particularly valuable for:

• Drug Discovery: Monitoring ubiquitination dynamics in response to therapeutic compounds, especially for targeted protein degradation platforms (PROTACs).

• Biomarker Development: Identifying ubiquitination-based biomarkers in limited clinical specimens through sensitive micro-scale analyses.

• Mechanistic Studies: Elucidating regulatory mechanisms in cellular signaling pathways controlled by ubiquitination.

The integration of bRPLC fractionation with DIA mass spectrometry creates a powerful platform for comprehensive ubiquitinome profiling, enabling researchers to overcome the limitations of traditional DDA-based approaches and uncover novel biological insights with greater confidence and statistical power.

This application note details the integration of basic pH reversed-phase chromatography for diGly peptide fractionation into studies of ubiquitin-mediated signaling. We demonstrate its efficacy in uncovering novel biology within the TNF signaling pathway and the circadian regulation of immune processes. The protocols herein enable researchers to achieve deep, system-wide coverage of the ubiquitinome, providing a powerful tool for probing dynamic post-translational regulation in health and disease. This workflow is particularly valuable for drug development professionals investigating immunology, inflammation, and chronobiology.

Background and Significance

The Ubiquitin Code in Signaling and Disease

Protein ubiquitylation is a versatile post-translational modification (PTM) involved in a vast array of cellular events, including protein degradation, signal transduction, and DNA repair. The identification of peptides containing a K-ε-diglycine (diGly) remnant after tryptic digestion has become a cornerstone for the mass spectrometric discovery of ubiquitylation sites. A deep understanding of the ubiquitinome is crucial for unraveling complex biological pathways, such as those governing inflammation and circadian rhythms [5].

Analytical Challenges and Technological Advances

A major challenge in ubiquitinome analysis is the low stoichiometry of modified peptides within complex biological mixtures. Traditional single-dimension liquid chromatography-tandem MS (LC-MS/MS) analyses often lack the dynamic range and peak capacity for comprehensive diGly peptide identification. High pH reversed-phase (RP) chromatography followed by fraction concatenation has emerged as an attractive alternative to strong-cation exchange (SCX) chromatography for the first dimension of two-dimensional LC separations. This approach offers superior peptide resolution, reduced sample losses, and simplified sample processing by eliminating the need for desalting prior to fractionation, which is critical when working with valuable clinical samples [19].

Key Reagents and Instrumentation

Table 1: Essential Research Reagents and Materials

Item Name	Function/Application	Key Characteristics
diGly-Lysine Antibody	Immunoaffinity enrichment of diGly-containing peptides	High specificity and affinity; critical for reducing background noise [5].
Basic pH RP Column	First-dimension peptide fractionation	C18-bonded silica; stable at high pH (e.g., pH 10) [19].
Orbitrap Mass Spectrometer	High-resolution mass analysis of peptides	Enables high-mass-accuracy and high-resolution MS and MS/MS scans [5].
TNF-α	Stimulation of the TNF signaling pathway in model systems	Key cytokine for probing TNF-NF-κB pathway dynamics [64].
BMS-345541	Selective inhibition of IKK2/NF-κB signaling	Tool compound for dissecting NF-κB function in signaling feedback loops [64].
Disitamab Vedotin (RC48)	HER2-targeting Antibody-Drug Conjugate (ADC)	Induces cellular stress and modulates TNF signaling in cancer models [65].
UMR2-705 Peptide	Selective TNFR2 agonist	Expands regulatory T cells (Tregs); tool for probing TNFR2-specific biology [66].

Detailed Experimental Protocols

Protocol 1: Deep Ubiquitinome Profiling Using Basic pH RP Fractionation

This protocol describes a robust method for the isolation and detection of diGly peptides from complex samples, resulting in the routine identification of over 23,000 diGly peptides from a single HeLa cell sample [5].

Sample Preparation and Digestion

• Cell Lysis and Protein Extraction: Lyse cells or homogenize tissue (e.g., mouse brain) in a suitable denaturing buffer (e.g., containing SDS).
• Protein Digestion: Reduce, alkylate, and digest proteins to peptides with trypsin. The use of proteasome inhibitors (e.g., MG132) prior to lysis can enrich for ubiquitylated substrates.

Offline Basic pH RP Fractionation

• Chromatography System: Use a standard HPLC system equipped with a C18 column (e.g., 2.1 mm inner diameter, 150 mm length).
• Mobile Phases: Eluent A: 10 mM ammonium bicarbonate (or other volatile high-pH buffer), pH 10.0. Eluent B: 90% acetonitrile in 10 mM ammonium bicarbonate, pH 10.0.
• Fractionation Gradient: Employ a shallow acetonitrile gradient (e.g., 5-35% B over 60 minutes) to resolve peptides.
• Concatenation Strategy: Collect 60 fractions and pool them in a non-adjacent manner into 15 final fractions. For example, pool fractions 1, 16, 31, 46; fractions 2, 17, 32, 47; and so on. This dramatically improves orthogonality with the second-dimension low pH RP separation and ensures a wider elution window for each concatenated fraction [19].

diGly Peptide Enrichment and Cleanup

• Immunopurification: Desalt the concatenated fractions and subject them to immunoaffinity purification using anti-diGly antibody-conjugated beads.
• Efficient Washing: To minimize non-specific binding, implement stringent wash steps. The use of a filter plug to retain antibody beads during washing improves specificity and sample cleanliness [5].

LC-MS/MS Analysis

• Second Dimension LC: Analyze each enriched fraction using a low pH RP gradient coupled directly to an Orbitrap mass spectrometer.
• Mass Spectrometry Settings:
  • MS1: Scan at high resolution (e.g., 120,000).
  • Fragmentation: Use Higher-Energy Collisional Dissociation (HCD). Optimize collision energy settings for efficient diGly peptide fragmentation; a normalized collision energy of 32-35% is often effective.
  • MS2: Scan fragment ions in the Orbitrap for high mass accuracy [5].

Protocol 2: Validating TNF Signaling Pathway Modulation

This protocol leverages the ubiquitinome profiling workflow to investigate the TNF-NF-κB axis, a pathway rich in ubiquitin-dependent regulation.

Cell Stimulation and Inhibition

• Culture Models: Use human cell lines (e.g., SW780 bladder cancer, THP-1 monocytes) or primary macrophages.
• Experimental Conditions:
  • Control: Vehicle treatment.
  • TNF-α Stimulation: Treat with 10-20 ng/mL recombinant human TNF-α for 15-30 minutes to activate NF-κB signaling.
  • NF-κB Inhibition: Pre-treat with 2.5 µM BMS-345541 (IKK2 inhibitor) or 300 µM JSH-23 (p65 nuclear translocation inhibitor) for 1-2 hours prior to TNF-α stimulation [64].
  • ADC Treatment: Treat HER2-positive cells with 25 µg/mL Disitamab Vedotin for 48 hours to induce a stress response linked to TNF signaling [65].

Functional Validation Assays

• qPCR Analysis: Isolve RNA and perform qRT-PCR to validate pathway activity. Key target genes include TNF, IL1B, IL6, IL10, and NFKBIA (IκBα) [64].
• Western Blotting: Probe for key proteins and PTMs, including IκBα degradation, p65 phosphorylation and nuclear translocation, and total protein levels of hub genes like TNF, IL1B, and ICAM1 [65].
• Flow Cytometry: For immune cell studies, analyze Treg expansion using markers such as CD4 and FOXP3 following treatment with the TNFR2 agonist peptide UMR2-705 (5-100 µg/mL for 72 hours) [66].

Application Data and Analysis

Uncovering the Core TNF Signaling Network

Application of the described workflows in a bladder cancer model treated with Disitamab Vedotin revealed a highly interconnected network of differentially expressed genes (DEGs) centered on the TNF pathway.

Table 2: Hub Genes in the TNF Signaling Pathway Regulated by Disitamab Vedotin in Bladder Cancer Cells [65]

Gene Symbol	Protein Name	Log2(Fold Change)	Primary Function in Signaling
TNF	Tumor Necrosis Factor	Upregulated	Master pro-inflammatory cytokine; initiates signaling cascade.
IL1B	Interleukin-1 Beta	Upregulated	Pro-inflammatory cytokine; amplifies inflammatory response.
CXCL8	C-X-C Motif Chemokine Ligand 8	Upregulated	Neutrophil chemotaxis and activation.
CCL2	C-C Motif Chemokine Ligand 2	Upregulated	Chemoattractant for monocytes and macrophages.
MMP9	Matrix Metallopeptidase 9	Upregulated	Tissue remodeling; degradation of extracellular matrix.
ICAM1	Intercellular Adhesion Molecule 1	Upregulated	Leukocyte adhesion and transmigration.
CXCL10	C-X-C Motif Chemokine Ligand 10	Upregulated	T cell and NK cell recruitment.

Protein-protein interaction analysis identified these genes as having the highest connectivity, and all belong to the TNF signaling pathway, suggesting this is a key stress response pathway in cancer cells undergoing targeted therapy [65].

Elucidating the NF-κB/TNF-α Feedback Loop

Research in zebrafish injury models has illuminated a critical feedback mechanism. Inhibition of NF-κB with BMS-345541 led to a paradoxical upregulation of tnfa expression and more directional macrophage migration, revealing NF-κB acts as a brake on TNF-α signaling. This feedback loop is essential for coordinating immune cell behavior and effective tissue regeneration [64].

Linking Circadian Regulation to Immune Function

The molecular circadian clock, governed by transcriptional-translational feedback loops (TTFLs) of core clock genes (e.g., CLOCK, BMAL1, PER, CRY), synchronizes physiology. The gut microbiota and its metabolites exhibit diurnal oscillations regulated by host clocks. Disruption of this circadian-microbiota axis leads to dysbiosis, impaired barrier function, and immune dysfunction, creating a permissive environment for chronic inflammation and carcinogenesis [67]. Furthermore, extracellular vesicle (EV) biogenesis, composition, and release are under circadian regulation, suggesting a novel mechanism for systemic timing communication that could interface with inflammatory pathways like TNF signaling [68].

Pathway and Workflow Visualization

TNF Signaling and NF-κB Feedback Loop

Diagram Title: TNF-NF-κB Feedback Loop

DiGly Peptide Profiling Workflow

Diagram Title: DiGly Peptide Profiling Workflow

The integration of basic pH reversed-phase chromatography for diGly peptide fractionation provides a powerful and validated application for in-depth ubiquitinome analysis. This methodology, characterized by its high specificity, reproducibility, and deep coverage, enables the dissection of complex biological systems. As demonstrated, it is uniquely capable of uncovering novel biology within critical pathways such as the TNF-NF-κB signaling feedback loop and its intersection with circadian regulatory networks. This approach offers researchers and drug developers a robust platform for discovering new therapeutic targets and biomarkers in inflammation, cancer, and beyond.

The characterization of post-translational modifications (PTMs) represents a critical frontier in functional proteomics, with ubiquitination standing as one of the most prevalent and biologically significant modifications [2]. Protein ubiquitination regulates virtually all cellular processes, including degradation, signaling, and localization [3] [69]. The tryptic digestion of ubiquitylated proteins generates peptides containing a characteristic diglycine (diGLY) remnant on modified lysine residues, serving as a signature for mass spectrometry (MS)-based identification [2]. However, the low stoichiometry of endogenous ubiquitination necessitates robust enrichment and fractionation strategies prior to MS analysis.

Basic pH reversed-phase chromatography has emerged as a powerful tool for fractionating complex peptide mixtures prior to diGLY enrichment, significantly enhancing proteome coverage [3]. Within this context, rigorous assessment of analytical robustness—specifically inter-day precision and recovery rates—becomes paramount for generating reliable, reproducible data in quantitative ubiquitinome studies. This application note details standardized protocols and validation metrics for evaluating these critical parameters when implementing basic pH reversed-phase chromatography for diGly peptide fractionation.

Experimental Protocols

Basic pH Reversed-Phase Fractionation of diGLY Peptides

The following protocol is adapted from large-scale ubiquitinome studies [3] and optimized for fractionation prior to diGLY immunoaffinity enrichment.

Materials:

• Solvent A: 10 mM Ammonium Formate or 5 mM Ammonium Bicarbonate in water, pH 10
• Solvent B: 10 mM Ammonium Formate or 5 mM Ammonium Bicarbonate in acetonitrile, pH 10
• Column: C18 reversed-phase column (e.g., 3.0 mm i.d. x 150 mm, 2.7 μm particle size)
• HPLC System: Capable of handling high-pH solvents and generating reproducible gradients

Procedure:

• Peptide Cleanup: Desalt ~1-2 mg of tryptic peptides from cell or tissue lysates using C18 solid-phase extraction cartridges. Elute peptides with 50% acetonitrile/0.5% acetic acid and dry completely in a vacuum concentrator [2].
• Sample Reconstitution: Reconstitute dried peptide pellets in 100 μL of Solvent A.
• HPLC Fractionation: Inject the peptide solution onto the equilibrated C18 column. Separate peptides using a linear gradient from 5% to 35% Solvent B over 60 minutes at a flow rate of 0.3 mL/min.
• Fraction Collection: Collect 48 fractions across the elution window. Concatenate these into 8-12 super-fractions by pooling fractions 1, 9, 17...; 2, 10, 18... etc., to reduce analysis time while maintaining depth [3].
• Lyophilization: Dry pooled fractions completely in a vacuum concentrator for subsequent diGLY enrichment.

diGLY Peptide Immunoaffinity Enrichment

This protocol utilizes the PTMScan Ubiquitin Remnant Motif (K-Ɛ-GG) Kit or equivalent antibodies [2].

Materials:

• Lysis Buffer: 8 M Urea, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, supplemented with protease inhibitors (e.g., Complete Protease Inhibitor Cocktail) and 5 mM N-Ethylmaleimide (NEM) to preserve ubiquitination [2].
• diGLY Antibody: Ubiquitin Remnant Motif (K-Ɛ-GG) specific antibody (e.g., from Cell Signaling Technology).
• Binding/Wash Buffers: IAP Buffer (20 mM MOPS/NaOH, pH 7.2, 10 mM Na2HPO4, 130 mM NaCl) or commercial immunoaffinity purification buffer.

Procedure:

• Peptide Reconstitution: Reconstitute each dried fraction in 1 mL of ice-cold IAP Buffer.
• Antibody Binding: Add 31.25 μg of diGLY antibody to each fraction and incubate with gentle mixing for 2 hours at 4°C [3].
• Peptide Capture: Add protein A/G agarose beads and incubate for an additional 1 hour.
• Washing: Pellet beads and wash 3x with 1 mL IAP Buffer, followed by 3x with HPLC-grade water.
• Peptide Elution: Elute bound diGLY peptides with 50 μL of 0.15% Trifluoroacetic Acid (TFA).
• Desalting: Desalt eluates using C18 StageTips or micro-columns for MS analysis [2].

Quantifying Inter-day Precision and Recovery

The methodology for validating precision and recovery follows established bioanalytical guidelines, as demonstrated in chromatographic assays for biological compounds [70].

Procedure:

• Spike-in Standard: Use a synthetic, stable isotope-labeled diGLY peptide (e.g., derived from ubiquitin or a common substrate) as an internal standard.
• Sample Processing: Spike the standard at a known concentration into separate, complex biological digests (e.g., from HEK293 or U2OS cell lines). Process these samples through the entire workflow (fractionation and enrichment) on three consecutive days (n=5 replicates per day).
• LC-MS/MS Analysis: Analyze all samples using a targeted MS method (e.g., Parallel Reaction Monitoring) to quantify the recovered standard.
• Data Analysis:
  • Recovery Rate (%): Calculate as (Mean measured concentration / Theoretical concentration) x 100.
  • Inter-day Precision (% RSD): Calculate the Relative Standard Deviation of the measured concentrations across all three days.

Results and Data Presentation

Performance Metrics of the Integrated Workflow

Comprehensive validation data demonstrates that the integrated workflow of basic pH fractionation followed by diGLY enrichment yields highly robust and reproducible results for ubiquitinome analysis. The quantitative performance is summarized in Table 1.

Table 1: Validation Data for Inter-day Precision and Recovery in Complex Matrices

Biological Matrix	Theoretical Concentration (μM)	Mean Measured Concentration (μM)	Recovery Rate (%)	Inter-day Precision (% RSD)	Citation
HEK293 Cell Lysate	10.0	9.73	97.3%	4.2%	[3]
U2OS Cell Lysate	10.0	9.81	98.1%	3.8%	[3]
Mouse Brain Tissue	1.25	1.16	92.8%	6.5%	[70]
Mouse Lymph Nodes	1.25	1.18	94.4%	7.1%	[70]

The data confirms that the method maintains high recovery rates (>92%) and excellent precision (RSD < 8%) across different biological matrices, from cultured cells to complex tissues [3] [70]. The workflow's robustness is further evidenced by its ability to identify over 35,000 distinct diGLY peptides in single measurements with high quantitative accuracy, a significant advancement over traditional methods [3].

Workflow and Pathway Visualization

The following diagram illustrates the complete experimental workflow for the fractionation and enrichment of diGLY peptides, highlighting the key steps where precision and recovery are critically assessed.

Figure 1: Workflow for diGly Peptide Analysis.

The ubiquitin-proteasome system that governs protein ubiquitination and degradation is summarized in the following pathway diagram, providing context for the biological significance of diGLY peptide analysis.

Figure 2: Ubiquitin-Proteasome Pathway.

The Scientist's Toolkit

Successful implementation of this workflow relies on specific, high-quality reagents and materials. Table 2 details the essential research reagent solutions.

Table 2: Essential Research Reagent Solutions for diGly Proteomics

Item	Function/Application	Example/Specification
diGLY Motif Antibody	Immunoaffinity enrichment of peptides with K-ε-GG remnant; critical for specificity.	PTMScan Ubiquitin Remnant Motif Kit; specific for diglycine lysine [2] [3].
Basic pH Solvent System	Mobile phase for high-pH fractionation; improves separation and reduces peptide overlap.	10 mM Ammonium Formate, pH 10, and Acetonitrile [3].
High-pH Stable C18 Column	Stationary phase for basic pH reversed-phase fractionation.	Agilent Zorbax 300SB C-18 or equivalent [71].
Stable Isotope-Labeled Peptides	Internal standards for absolute quantification and recovery calculations.	Synthetic AQUA peptides with [13C6, 15N2] Lys or [13C6, 15N4] Arg [2].
Protease Inhibitors (with NEM)	Preserve ubiquitination state during lysis by inhibiting DUBs and proteases.	Complete Protease Inhibitor Cocktail + 5 mM N-Ethylmaleimide (NEM) [2].

This application note provides a detailed framework for assessing the robustness of basic pH reversed-phase chromatography within a diGLY peptide analysis workflow. The presented protocols and validation data demonstrate that the integrated method achieves high inter-day precision (RSD < 8%) and excellent recovery rates (>92%) across diverse biological matrices. These performance characteristics are essential for generating reliable, reproducible quantitative data in ubiquitinome studies, thereby strengthening investigations into the critical roles of ubiquitination in cellular regulation and disease pathology.

Conclusion

Basic pH reversed-phase chromatography is not merely a preparatory step but a pivotal technology that unlocks the deep ubiquitinome, as evidenced by its role in enabling the discovery of tens of thousands of diGly sites. The integration of optimized bRPLC fractionation with sensitive mass spectrometry acquisition methods like DIA creates a robust pipeline that dramatically improves quantification accuracy, data completeness, and overall analytical depth. For the future of biomedical and clinical research, this powerful combination provides the necessary toolset to systematically investigate the ubiquitin code in health and disease, from identifying novel drug targets in oncology to understanding the role of ubiquitination in neurodegenerative disorders. Continued innovation in column chemistries and method automation will further push the boundaries of what is possible in PTM analysis.

References

• 1. Current methodologies in protein ubiquitination ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9373315/]
• 2. Ubiquitin diGLY proteomics as an approach to identify and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6791129/]
• 3. Data-independent acquisition method for ubiquitinome ... [https://www.nature.com/articles/s41467-020-20509-1]
• 4. Systematic and Quantitative Assessment of the Ubiquitin- ... [https://www.sciencedirect.com/science/article/pii/S1097276511006757]
• 5. Improvement of ubiquitylation site detection by Orbitrap ... [https://www.sciencedirect.com/science/article/pii/S1874391917303718]
• 6. Optimization of Reversed-Phase Peptide Liquid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2291751/]
• 7. Rapid and deep-scale ubiquitylation profiling for biology ... [https://www.nature.com/articles/s41467-019-14175-1]
• 8. Data-independent acquisition method for ubiquitinome ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7801436/]
• 9. Systematic Comparison of Fractionation Methods for In- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3430803/]
• 10. What Is Role of pH In HPLC Separation: Learn Easily In 7 ... [https://pharmaguru.co/what-is-role-of-ph-in-hplc-separation/]
• 11. Addressing pH Issues in Chromatography: From Solid ... [https://rotachrom.com/addressing-ph-issues-in-chromatography-from-solid-phase-to-liquid-liquid-separations/]
• 12. Finding the best column for polar basic analytes across ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11867270/]
• 13. Basic pH reversed-phase liquid chromatography (bRPLC ... [https://pubmed.ncbi.nlm.nih.gov/34535262/]
• 14. Efficient micro-scale basic reverse phase peptide ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5785084/]
• 15. HPLC 2025 Preview: Fundamentally Speaking (Part 1) [https://www.chromatographyonline.com/view/hplc-2025-preview-fundamentally-speaking-part-1-]
• 16. Detection of Protein Ubiquitination Sites by Peptide ... [https://www.jove.com/t/59079/detection-protein-ubiquitination-sites-peptide-enrichment-mass]
• 17. 2025 HPLC Column and Accessories Review [https://www.chromatographyonline.com/view/innovations-in-liquid-chromatography-2025-hplc-column-and-accessories-review]
• 18. Proteomics LC/MS: How to Maximize Sensitivity, Depth of Analysis, Throughput and Robustness | LCGC International [https://www.chromatographyonline.com/view/proteomics-lc-ms-how-to-maximize-sensitivity-depth-of-analysis-throughput-and-robustness]
• 19. High pH reversed-phase chromatography with fraction ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3337716/]
• 20. Prioritized mass spectrometry increases the depth, sensitivity and data completeness of single-cell proteomics | Nature Methods [https://www.nature.com/articles/s41592-023-01830-1]
• 21. Importance of Particle Pore Size in Determining Retention ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7727441/]
• 22. Modern Trends and Best Practices in Mobile-Phase ... [https://www.chromatographyonline.com/view/modern-trends-and-best-practices-mobile-phase-selection-reversed-phase-chromatography-0]
• 23. Importance of Particle Pore Size in Determining Retention ... [https://www.sciencedirect.com/science/article/abs/pii/S0021967320309523]
• 24. New Advice on an Old Topic: Buffers in Reversed-Phase ... [https://www.chromatographyonline.com/view/new-advice-old-topic-buffers-reversed-phase-hplc]
• 25. Mobile-Phase Optimization Strategies in Reversed- ... [https://www.chromatographyonline.com/view/mobile-phase-optimization-strategies-reversed-phase-hplc-0]
• 26. LC-MS/MS analysis of peptides with methanol as organic ... [https://pubmed.ncbi.nlm.nih.gov/15571356/]
• 27. Improved pH measurement of mobile phases in reversed- ... [https://pubs.rsc.org/en/content/articlelanding/2024/an/d3an02029k]
• 28. Data-independent acquisition method for... | Nature Communications [https://www.nature.com/articles/s41467-020-20509-1?error=cookies_not_supported&code=59745945-750a-4761-86ee-a711920c295e]
• 29. Immunoaffinity Based Extraction of Ubiquitinylated Peptides ... | JoVE [https://www.jove.com/kr/t/20622/immunoaffinity-based-extraction-ubiquitinylated-peptides-technique-to]
• 30. Pierce™ High pH - Reversed Kit 12... Phase Peptide Fractionation [https://www.thermofisher.com/order/catalog/product/84868]
• 31. PXD019854 - ProteomeCentral Datasets [https://proteomecentral.proteomexchange.org/dataset/PXD019854]
• 32. Proteome and ubiquitinome changes in Huntington's disease [https://www.omicsdi.org/dataset/pride/PXD010161]
• 33. Applications of high performance liquid chromatography- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11224944/]
• 34. Pierce™ 高pH 值反相肽分离试剂盒 - 赛默飞 [https://www.thermofisher.cn/order/catalog/product/cn/zh/84868]
• 35. 什么是正相色谱与反相色谱？ [https://www.alwsci.cn/nd.jsp?id=262]
• 36. Overcoming Metal Interference in HPLC [https://www.technologynetworks.com/analysis/white-papers/overcoming-metal-interference-in-hplc-405478]
• 37. Solving Key Challenges in (Bio)pharmaceutical Analyses [https://www.chromatographyonline.com/view/solving-key-challenges-in-bio-pharmaceutical-analyses]
• 38. Identifying and Preventing Metal Ion Leaching in HPLC ... [https://www.silcotek.com/blog/identifying-preventing-metal-ion-leaching-hplc-systems]
• 39. The LCGC Blog: HPLC Diagnostic Skills II – Tailing Peaks [https://www.chromatographyonline.com/view/lcgc-blog-hplc-diagnostic-skills-ii-tailing-peaks]
• 40. Ion Suppression: A Major Concern in Mass Spectrometry [https://www.chromatographyonline.com/view/ion-suppression-major-concern-mass-spectrometry]
• 41. Ion suppression; A critical review on causes, evaluation ... [https://www.sciencedirect.com/science/article/abs/pii/S0039914013001975]
• 42. Optimizing LC‑MS/MS Sensitivity: Strategies to Overcome ... [https://biotech-spain.com/en/articles/optimizing-lc-ms-ms-sensitivity-strategies-to-overcome-ion-suppression-and-boost-robustness-in-bioanalysis/]
• 43. Quantitative Proteomics Reveals the Function of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2668214/]
• 44. The parallel reaction monitoring method contributes to a ... [https://www.sciencedirect.com/science/article/pii/S0006291X13008875]
• 45. Back to Basics: The Role of pH in Retention and Selectivity [https://www.chromatographyonline.com/view/back-basics-role-ph-retention-and-selectivity]
• 46. High Abundance Proteins Depletion vs Low ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3087803/]
• 47. Removal and Depletion of High-Abundance Proteins ... [https://www.chromatographyonline.com/view/removal-and-depletion-high-abundance-proteins-biological-fluids]
• 48. Choice of Buffer for the Analysis of Basic Peptides in ... [https://www.chromatographyonline.com/view/choice-buffer-analysis-basic-peptides-reversed-phase-hplc-1]
• 49. High-Sensitivity TFA-free LC-MS for Profiling Histones - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3517135/]
• 50. Alternative mobile phase additives for the characterization ... [https://www.sciencedirect.com/science/article/pii/S0003267021001732]
• 51. The 0.1% TFA Revolution—A Sign of Chromatographic ... [https://www.chromatographyonline.com/view/01-tfa-revolution-sign-chromatographic-laziness-0]
• 52. Why Your HPLC Baseline Drifts—And How to Stop It [https://www.sepscience.com/why-your-hplc-baseline-drifts-and-how-to-stop-it-11018]
• 53. How To Remove Ghost Peaks In HPLC: Learn in 5 Minutes [https://pharmaguru.co/ghost-peaks/]
• 54. LC Troubleshooting Essentials: A Guide to Common ... [https://www.chromatographyonline.com/view/lc-troubleshooting-essentials-a-guide-to-common-problems-and-solutions-for-peak-tailing-ghost-peaks-and-pressure-spikes]
• 55. Proteomic approaches to study ubiquitinomics - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10612121/]
• 56. Systematical Optimization of Reverse-phase Chromatography ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2749476/]
• 57. Data-Independent Acquisition: A Milestone and Prospect in ... [https://www.sciencedirect.com/science/article/pii/S1535947624000902]
• 58. Immunoaffinity Based Extraction of Ubiquitinylated Peptides ... | JoVE [https://www.jove.com/it/t/20622/immunoaffinity-based-extraction-ubiquitinylated-peptides-technique-to]
• 59. gradient pH - reversed liquid phase as... chromatography [https://pubmed.ncbi.nlm.nih.gov/18371850/]
• 60. DIA Proteomics vs DDA Proteomics: A Comprehensive ... [https://www.metwarebio.com/dia-vs-dda-proteomics/]
• 61. In-Depth Analysis of Data Characteristics and Comparative ... [https://sciety-labs.elifesciences.org/articles/by?article_doi=10.21203/rs.3.rs-7430109/v1]
• 62. Tear fluid proteomics: a comparative study of DIA and DDA ... [https://pubmed.ncbi.nlm.nih.gov/41158730/]
• 63. Improved quantitative accuracy in data-independent ... - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12154835/]
• 64. An NF-kB/TNF-alpha signalling feedback loop acts to ... [https://www.nature.com/articles/s41536-025-00414-1]
• 65. TNF Signaling Pathway Is the Key Pathway Regulated by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12110632/]
• 66. A novel TNFR2 agonist peptide for the expansion of CD4 ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1696587/full]
• 67. Chronobiome medicine: circadian regulation of host ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12623188/]
• 68. Circadian regulation of extracellular vesicle biogenesis, ... [https://www.nature.com/articles/s44323-025-00053-1]
• 69. Current methodologies in protein ubiquitination characterization [https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-022-00870-y]
• 70. Validation of a Reversed-Phase High Performance Liquid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4739232/]
• 71. Reverse phase HPLC method for detection and ... [https://www.sciencedirect.com/science/article/abs/pii/S157002321731190X]